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Tendon injuries account for roughly half of the 33 million musculoskeletal injuries that 
occur every year. Of all patients seeking nonsurgical treatment, 29% eventually require surgery. 
The use of autografts, allografts, and xenografts have limitations associated with donor site 
morbidity, availability, and immunogenicity. Tissue engineering has emerged as a feasible 
approach to find treatments for injuries requiring tissue replacement through biodegradable 
scaffolds, stem cells, and biomolecules. 
Tissue engineering scaffolds serve to provide a temporary, biomimetic template for cells, 
as well as act as delivery vehicles for biomolecules, such as growth factors. Growth factors have 
been widely popular in tissue engineering owing to their importance in embryonic development 
and healing. Insulin-like growth factor-1 (IGF-1) has been extensively researched for its ability to 
encourage cell proliferation, inhibition of cell apoptosis, and collagen formation. The homology 
of insulin and IGF-1, structurally, as well as biologically, has motivated various comparative 
studies, as well as investigations in the use of insulin for tissue engineering applications. This work 
explored insulin as a bioactive factor in promoting tendon regeneration and investigated insulin 
delivery through electrospun blend fibers made from synthetic polymer, polycaprolactone and 
natural material, cellulose acetate.     
The treatment of human mesenchymal stem cells (MSCs) with concentration of 100ng/ml 
showed increased expression of tendon related genes and ECM proteins, suggesting phenotypic 
development of MSCs towards tendon lineage. Insulin functionalized scaffolds were observed to  
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support tendon differentiation of MSCs, in-vitro. The bioactive scaffolds were implanted in a rat 
Achilles tendon model and found to encourage better healing through greater collagen deposition 
and fiber organization. However, no significant findings were found in mechanical properties of 
the healed tissue when compared to control groups. Increase in collagen and matrix organization 
with no difference in mechanical property warrants further research in functional analysis of the 
tendon and exploration into possible early immunomodulation effects. For the first time, insulin 
has been investigated for use in tendon tissue engineering applications and shown to achieve better 
ECM organization with use of a bioactive insulin functionalized scaffold.  
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Chapter 1: Tendon and Tissue Engineering Overview 
 
1! Tendon Overview 
 
The human musculoskeletal system is a coordinated system of connective tissue that work 
in concert to bring stability to the body and allow for the myriad of daily human activities. Tendon 
is an important tissue that connects muscles to bones and whose primary function is to mediate 
movement and bring stability to joints. This chapter gives a brief overview of tendon structure, 
biomechanics, as well tendon injuries and current treatments.   
 
Figure 1.1. Overview of tendon extracellular matrix.  
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1.1!Tendon structure and extracellular matrix composition  
Tendon structure is greatly governed by its function, thus slight variations in morphology 
and organization exists between tendons in different locations. Tendons that are connected to 
muscles that generate strong, resistive forces, such as the quadriceps are short and broad, whereas 
flexor tendons, located in the fingers, are long and thin (1). Irrespective of their location, healthy 
tendons exhibit shiny white appearances and are composed of dense parallel bands of collagen 
fibers arranged in a hierarchical structure. It is this unique organizational structure that endows 
tendon tissues with high mechanical strength.  
The major constituent of tendon is collagen fibers, which make up 85% of the total dry 
weight (2). The fundamental building blocks of collagen fibers is procollagen, which is made up 
three polypeptide chains that are arranged in a helical structure. Tendon fibroblast cells secret 
procollagen into the extracellular matrix, where they are cleaved to form tropocollagen (3). 
Tropocollagens are roughly 1.5nm in diameter and self-assemble to form aggregates of 
tropocollagen molecules called microfibrils, which then give rise to fibrils (4). Fibrils range from 
100-500nm in diameters (5) and under scanning electron microscopy, can be seen as black and 
white striated bands (3). Fibrils combine to form tendon fibers that are 10µm in dimeter. These 
collagen fibers are visible under light microscopy and display a crimp like pattern when unloaded. 
The sinusoidal pattern facilitates 1-3% elongation of the tendon, which serves as a buffer to sudden 
mechanical loading (5). Collagen fibers are arranged in bundles to form tendon fascicles, which in 
turn make up the tendon body. Individual tendon fascicles are surrounded by connective tissue 
known as endotenon, which links to the epitenon, which surrounds the entire tendon body (4). The 
hierarchical structure of the tendon is displayed in Figure 1.  
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In addition to collagen I, other collagen types in smaller amounts are also present in tendon. 
In healthy tendon collagen III is found at the endotenon and epitenon, but is also present in higher 
numbers in aging and injured tendons. Compared to collagen I, collagen III forms smaller and less 
organized fibrils, with lower mechanical strength. Collagen V is intercalated into the core of 
collagen I and is involved in the regulation of fibril growth. Collagen II, VI, IX, X, and XI have 
also been found in trace amounts in tendon, mainly at the bony insertion site (6).  
 
1.1.1! Ground Substance     
The surrounding tissues that encase the collagen fibers are referred to as the ground 
substance. The ground substance is composed of proteoglycans, glycosaminoglycans, 
glycoproteins and other small molecules (1). Proteoglycans are large hydrophilic molecules, 
dispersed between within and between collagen fibrils, that are capable of absorbing water 50 
times their weight. Proteoglycans are composed of a protein core with covalently bonded 
glycosaminoglycans (GAGs) (1). Higher concentration of GAGs are found in tendons subjected 
to higher compressive forces (7). Under SEM, proteoglycans are seen as filaments attached to 
collagen fibrils (8). Proteoglycans serve to aid in resisting high compressive and tensile forces. 
Additionally, they allow for cell migration and rapid diffusion of water soluble molecules. 
Aggrecan is known to retain water in the ECM, whereas decorin was observed to facilitate 
fibrillary slippage. The most predominant proteoglycan in tendon is decorin and may be involved 
in the regulation of fiber diameter (2). Animal models with mutations lacking decorin showed 
irregular diameters of collagen fibrils (8), whereas downregulation of decorin was associated with 
the development of collagen fibrils with larger diameters and higher tensile strengths in ligament 
scar (8, 9).  
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 Glycoproteins in tendons include fibronectin and tenascin-C. Fibronectin is found on the 
surface of collagens and is involved in wound healing. Tenascin-C interacts with collagen fibrils 
to aid in mechanical stability of the ECM (6). Tenomodulin is a transmembrane glycoprotein 
observed to be involved in tendon maturation and is considered to be highly specific to developing 
tendons.  
 
1.1.2! Cells 
Tendon fibroblasts are the dominant cell type in tendons and are referred to as tenoblasts 
and tenocytes. These fibroblasts reside in rows parallel to and between collagen fibers. They are 
responsible for synthesizing ECM proteins such as collagen and proteoglycans. At early 
developmental stages, such as newborns, there is a high cell-to-matrix ratio in the tendons, with 
varying shapes and sizes. As tendon matures, the cell-to-matrix ratio decreases and cells become 
more elongated and transform to tenocytes. Mature tenocytes have long processes to maintain 
close contact with few surrounding cells and matrix components (1), with high nucleus-to-
cytoplasm ratio and lower metabolic activity (7).  
Other cells present in tendons include chondrocytes, synovial cells, and endothelial cells 
(6). Additionally, the presence of tendon stem cells has also been discovered. Bi et al. discovered 
a unique population of mesenchymal stem cells (10). These tendon-derived mesenchymal stem 
cells have been shown to self-renew and have the same tri-differentiation properties as that of other 
mesenchymal stem cells (11). It is believed these tendon stem cells play a critical role in the tendon 
maintenance and repair, but may also potentially play a role in the development of tendinopathy 
through aberrant differentiation (12).  
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1.1.3! Tendon Vascularity  
Though the amount of vascularization and source vary depending on the tendon location 
and function. When compared to other tissues, overall tendon ECM has limited vascularity. 
Tendons thus derive nutrients from their attachments, at both the bony or muscle ends or from the 
surrounding paratenon, which is known to be the main source of vascularity (3). Vascularization 
decreases with maturation, with significantly more blood supply during development. Vascular 
endothelial growth factor, a known simulator of angiogenesis, is upregulated in tendon during 
development and the period following injury.   
 
1.1.4! Tendon Biomechanics 
The unique structure and composition of tendon endows tendon tissues with unique 
biomechanical properties such as high mechanical strength and viscoelasticity. As the connective 
tissue between muscles and bones, tendons undergo large amounts of tensile loading. Mechanical 
behavior of tendon can be described in stress strain diagram with 4 regions. Below 2% strain, is 
the toe region, where the crimped shaped collagen fibers, as previously described, are stretched 
and begin to straighten out. Below 4% strain, is the elastic region. The collagen fibers are oriented 
in the direction of the tensile load. If subjected to higher strains, the tendon is stretched beyond its 
physiological limit and microscopic tears in the fibers begin to appear. Beyond 8-10% strain, 
macroscopic tears occur, leading to tendon ruptures (12). 
Tendons are can be described as having viscoelastic properties, which simply means 
tendons display both elastic and viscous behavior.  Elastic materials will return to their original 
length if within the elastic region, whereas viscoelastic materials have a time dependent strain rate. 
Thus tendons display more deformation at low strain rates than at high strain rates. Slow strain 
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rates result in tendons absorbing more mechanical energy and becoming less effective in 
transmitting loads. At high strain rates, tendons become stiffer, absorb less mechanical energy and 
thus can more effectively transmit the mechanical force to the attached bone. This viscoelastic 
property of tendons is attributed to water, collagenous proteins, proteoglycans, and their 
interactions (12).   
 
1.1.5! Response to Mechanical Loading 
 In the past most of our understanding of tendon adaption to mechanical loading, has been 
provided through animal models due to the difficulty of evaluating human tendons. Animal models 
subjected to physical activity compared to controls showed structural changes in tendon strength 
and appearance (6). The ultimate load and energy absorbed at failure of the brevis tendon (tendon 
in the foot) was increased in rabbits subjected to 40 weeks of exercise (13, 14). The adaptability 
of tendons to mechanical loading was observed in a mouse study. In mice subjected to daily 
treadmill exercise, changes in fibril diameter, number and cross sectional area were observed, 
increasing one-week post treatment and decreasing during the 3-7th week of the study. Long term 
effects showed increase  in overall fibril number, but not in mean diameter, or cross sectional area 
(15). Other studies have shown the increase of collagen deposition following strenuous endurance 
training in the Achilles tendon of roosters (16).   
On the opposite spectrum, the effects of immobilization on tendons have also been studied.  
In general, due to the lower metabolic rate and vascularity of tendons, atrophy due to 
immobilization is less pronounced and dramatic when compared to other musculoskeletal tissues 
(17).  Following an Achilles tendon rupture, the healing of rabbits immobilized at the knee joint 
versus rabbits who were immobilized at both the knee and ankle joint were compared after 4 weeks 
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(18). Rabbits immobilized at the knee and ankle joints had decreased ultimate stress and stiffness 
of the Achilles tendon, as well as the formation of irregular and uneven collagen fibers, dilated 
veins and capillaries. The authors hypothesized that immobilization retards the healing of the 
ruptured tendons due to congestion and tension deprivation. Dramatic changes in tendon cell 
shape, cell number, and collagen fiber alignment have also been observed in immobilized tendons 
(19). 
Studies looking into the overuse of tendons look at the effects of chronic exposure to 
excessive loading. Advances in non-evasive imaging such as MRI and ultrasound, has made it 
possible to evaluate the effect of physical activity on human tendons. In humans, Rosager et al. 
evaluated MRI images of Achilles tendons in long distance runners, (defined as those who ran 
more than 80km a week) and compared them to age matched controls. Larger cross-sectional areas 
of the tendon was observed in runners (20). The increase in cross-sectional area is hypothesized to 
reduce the average stress caused by the repetitive loading of running. Tendinopathy is believed to 
be caused by repetitive mechanical loading that cause strains below the failure threshold, which in 
turn cause microinjuries and inflammation (6).  
In general, animal models have shown that tensile strength, elastic stiffness, and total 
weight of the tendons tend to gradually increase with gradually increasing physical activity due to 
increased thickness of collagen fibrils and fibers. This results in larger and stronger tendons with 
increased resistance to injuries. However, if excessive loading is applied, the sum effect may be 
detrimental and cause inflammation (17). Despite the research that has been done, much is still 
unknown regarding tendon adaption to physical activity in humans (6).  
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1.1.6! Tendon Injury and Healing 
1.1.6.1!Injury  
It is estimated that 50% of the 33 million musculoskeletal injuries are related to tendon or 
ligament damage (5, 21). The most common tendinopathies pertain to the rotator cuff tendons, 
medial and lateral elbows, patellar, and Achilles tendon. These tendons are known to be more 
highly stressed than others, are subjected to repeated strains, and are less vascularized at their 
midsubstance (22).   
Tendon injuries can be divided into two subclasses: 1) acute and 2) chronic degeneration. 
Though acute injuries can be caused by trauma, spontaneous ruptures may be a result of chronic 
injuries due to accumulation of microtears that generate an aberrant tendon matrix (23). 
Tendinopathies include inflammatory related injuries such as tendinitis as well as non-
inflammatory conditions such as tendinosis and ruptures (21). Histology of injured tendons are 
amorphous, grey brown in appearance and display disorganized collagen, with increased 
cellularity, neovascularization, and proteoglycan ground substance (24). Though the etiology of 
tendinopathy remains elusive, Sharma et al. summarizes the possible causes to ischemia, hypoxia, 
tenocyte apoptosis, or presence of cytokines and inflammatory prostaglandins (25), all of which 
can be brought on by excessive mechanical loading and overuse. 
   
1.1.6.2!Healing  
Healing is limited due to lower vascularity and hypocellularity.  Tendon healing is often 
described in three stages 1) inflammatory, 2) proliferative, and 3) remodeling. The first stage of 
healing can last for several days and is marked by the infiltration of erythrocytes and neutrophils. 
Macrophages and monocytes in the area remove necrotic material, while vasoactive and 
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chemotactic factors are released. Tenocytes migrate to the area and begin to produce collagen III. 
During the proliferative stage, more collagen III is synthesized and there is an upregulation of 
water and glycosaminoglycan content. This stage can last for a few weeks before the remodeling 
stage begins. The first half of the remodeling stage can be described as the consolidation stage. At 
this point, during 6-10 weeks post injury, the injured tissue changes from cellular to fibrous and 
alignment of cells and collagen fibers begin to orient along the direction of stress. Collagen I 
synthesis is highly upregulated. After 10 weeks, the tendon transitions to the maturation phase 
which may last for year and tendon scar tissue is developed. At the end of healing, tenocyte 
metabolism and vascularity start to decrease.  
 
1.1.7! Treatment Modalities  
Tendon injuries are clinically treated with either conservative or surgical interventions. 
Conservative treatments include physical therapy and injections of non-steroidal anti-
inflammatory drugs (NSAIDS) or corticosteroids.  Non-surgical treatments have been shown to be 
less successful with 29% of patients eventually needing surgical treatment (21, 26). Surgical 
treatment often involves debridement of injured tissues and reattachment of the tendon using an 
allograft, graft from cadaver, autograft, graft from secondary area of the body, or xenografts, grafts 
from animals. Information on the performance of commercial grafts is further discussed in Chapter 
5. Current grafts on the market have been met with variable results and high retear rates, and 
observed to treat only pain with little functional gains (27, 28).   
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2! Tissue Engineering Overview 
Regenerative capacity of the human body has long been speculated through ancient myths 
and stories. Today, science has shown that regenerative capacity is not only possible, but tissue 
regeneration is being exploited to its greatest extent. The discovery of stem cells, in parallel to the 
increasing knowledge of cell biology and the biomedical sciences, has contributed to the growing 
field of regenerative and tissue engineering. Various tissues and organs are being studied in hopes 
of finding solutions to human diseases and injuries. Tissue engineering, as defined by Dr. Langer 
and Dr. Vacanti, is an interdisciplinary field which applies the principles of engineering and life 
science toward the development of biological substitutes that restore, maintain, or improve tissue 
function (29). Strategies for tissue engineering often encompass the use of biomaterials, cells and 
biomolecules, separately or in combination to regenerate tissues or whole organs. What began as 
a science fiction is soon becoming a reality as scientists are developing new ways to incorporate 
biomaterials into the body to heal and regenerate various tissues and organs. The following 
sections will give an overview of tissue engineering principles as it relates to tendon regeneration. 
 
2.1.1! Evolution of Biomaterials 
Throughout history it was discovered that several metals such as silver, copper, and gold 
could stay in the body without causing an immunogenic reaction. Today, metal implants are made 
from stainless steel and cobalt base alloys and titanium. Though still widely used in a variety of 
biomedical applications such as hip replacements and orthopaedic fixation devices, stress shielding 
of metal implants is a problem as the mechanical mismatch of natural tissues versus metal implants 
proved to be detrimental to the surrounding tissue. By implanting structures that were significantly 
stronger than the surrounding body environment, the surrounding muscles atrophied and became 
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weaker. Initially, such implants were thought of as inert and served only as place holders. 
Additionally, problems with infections and necessary revision surgeries contribute to the 
limitations of metal implants.  
 Today the properties of the native tissue govern the design of implants or scaffolds in 
tissue engineering in hopes of regenerating new tissue. Scaffolds are designed to degrade in-situ, 
and to be eventually replaced with native tissue. Further details on materials for tendon tissue 
engineering applications are discussed in Chapter 4. To stimulate regeneration, tissue engineering 
strategies utilize cells, as well as biochemical and physical cues given by the scaffold and bioactive 
molecules. 
 
2.1.2! Exogenous Cells 
The exact role of exogenous cells in regeneration remains unanswered. Some studies 
suggest cells play a direct role in laying new extracellular matrix for the regenerate tissue, while 
other studies show that cells have a more paracrine effect, serving only to recruit native cells to 
the injury site. The answer may lie somewhere in the middle, with cells playing both direct and 
indirect roles in regeneration. Nevertheless, the addition of exogenous cells are observed to have 
a beneficial effect and to aid in tissue engineering (30, 31).  
Several types of cells have been applied towards tendon tissue. Tendon fibroblast cells 
have been studied, but their low availability limits their use. As previously mentioned, tendon is 
hypocellular, thus obtaining the desired number of tenocytes poses to be a challenge. Embryonic 
stem cells may have great potential in regenerating tendon, as it has been shown that the fetal 
tendon maintains the ability to regenerate, even after being transplanted into an adult environment 
(32). This indicates the regenerative capacity of the tendon is intrinsic to the tissue itself and not 
the environment. However, the legal and moral controversies surrounding the use of embryonic 
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stem cells limits their wide spread use. The limitations of tendon fibroblasts and embryonic stem 
cells make adult progenitor cells attractive for use in tendon tissue engineering. Mesenchymal stem 
cells (MSCs) are adult stem cells that have the capacity to differentiate into cartilage, bone, 
adipose, neurons, muscles, tendon, ligaments, dermis and other connective tissues (33). These cells 
have been extracted from a variety of sources including bone marrow, adipose, and tendon. 
Induced pluripotent stem cells (iPSCs), terminally differentiated cells that have been 
dedifferentiated into back into stem cells, have also been explored for tendon applications.  Though 
there is a growing interest in iPSCs, and much research has gone into their potential in tissue 
engineering, they are far from clinical use. By far, the most popular cell type and most clinically 
relevant is MSCs due to their versatility and relative abundance.  
 
2.1.3! Mechanical Stimulation 
Mechanical stimulation has been observed to play a critical role in tissue regeneration of 
load-bearing tissues, such as tendon. Custom bioreactors have been designed to provide 
mechanical stimulation to cell-seeded constructs to observe effects of mechanical stimulation, in-
vitro.  Shearn et al. developed a pneumatic mechanical stimulation system to provide mechanical 
strain to stem cell seeded collagen sponge constructs and observed increased stiffness in the 
stimulated constructs (34) with increased gene expression of collagen I and III (35). Xu et al. found 
greater proliferation and enhanced differentiation of tendon derived stem cells with scaffolds that 
received mechanical stimulation (36). Though its commonly accepted that mechanical stimulation 
can modulate cellular behavior, the mechanism of how cells sense mechanical forces and convert 
them to chemical signals remains elusive.  
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2.1.4! Tendon Regulatory Factors  
When compared to other musculoskeletal tissues, the mechanistic drivers of tendon 
regulation remain largely unknown. For example, the absence of myogenic factors, Myf5, 
MyoD, and Mrf4 (40) leads to the loss of skeletal muscle in mice, whereas the absence of Sox9 
leads to complete absence of cartilage (41, 42). To date the absence of a singular factor has not 
been shown to prevent the complete disappearance of tendon formation. However, several 
factors have been observed to play crucial roles in the formation of proper tendon. Thus it is 
hypothesized that it is a concert of regulatory factors that give rise to tendon development (43, 
44). 
 
2.1.5! Embryonic Development  
 
Figure 1.2. Development compartments of the embryo.  
 
 
Through studying tendon embryonic development, researchers can piece together the 
biochemical signals conducive for tendon formation. The discovery of scleraxis as a tendon 
transcription factor has allowed researchers to more easily identify tendon progenitor cells and 
trace their embryonic origins.  The embryonic origin of tendon progenitor cells varies among trunk, 
craniofacial and limb tendons.  
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Trunk tendons or axial tendons connect muscles located along the spinal column to the 
vertebrate, providing stability to the spine and allows for extension, rotation and flexion. It was 
observed that the inception of axial tendon progenitor cells develops at the edge of sclerotome 
compartment adjacent to the myotome compartment of the somite. These scleraxis expressing cells 
are now described as a fourth compartment of the somite, called the syndetome. The syndetome is 
believed to be regulated from neighboring compartments (37). Tendon development of axial 
tendons have been observed to be largely dependent on muscle development, based on the studies 
showing the ablation of the dermomyotome before the formation of the myotome (embryonic 
origin of muscles) led to a lack of scleraxis expression in chick embryos. Thus tendon progenitor 
cells may derive from the sclerotome compartment, but require signals from the myotome (38). 
These signals are believed to be related to fibroblast growth factors (FGFs), whose absence 
resulted in loss of scleraxis expression. Cartilage precursor cells of the sclertome appear to regulate 
the specification of cells that form the syndetome. Expression of slceraxis required the 
downregulation of Pax1. Overexpression of Pax1 resulted in the inhibition of sleraxis expression 
in chicken embryos (37), whereas the inhibition of mutant mice lacking cartilage, showed a slight 
increase in scleraxis expression. Thus, the differentiation of tendon from the somite appears to be 
highly dependent on the combination of activating and suppressing signals from neighboring 
compartments.   
Craniofacial tendons originate from the neural crest, whereas limb tendons originate from 
the lateral plate region. Limb and craniofacial tendons have shown initial developments that are 
independent of muscle, however fail to progress in later stages, suggesting muscle is required for 
tendon maturation. It is hypothesized muscles provide the required mechanical forces that allow 
for tendon maturation. Results from studies looking parallel at bone and tendon embryonic 
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development have been mixed, suggesting tendon dependency on bone development may vary 
according to location and proximity. Further research into limb tendon development has shown 
the removal of the dorsal limb ectoderm resulted in the loss of scerlaxis expression (39) suggesting 
the ectoderm plays a critical role in tendon development. Specific ectodermal signals have not yet 
been identified.  
Transforming growth factor ! (TGF- !) superfamily proteins may also be involved in 
tendon development. In TGF-! null mice, most tendons and ligaments in the limbs, trunk, tail and 
head were gone. Moreover, it is suggested TGF-! is critical to forming tendon attachments to bone 
and muscles (40). The bone morphogenetic protein (BMP) family, which include growth and 
differentiation factor (GDF) proteins have also been recognized for their role in tendon 
development. In GDF null mice, abnormalities in the structure and biomechanical properties of 
tendons were present. Moreover, the fate of limb tendon progenitor cells has been shown to be 
regulated by both BMP and FGF signaling. The inhibition of BMP signaling resulted in tendon 
differentiation, whereas the inhibition of FGF signaling resulted in chondrogenesis in developing 
chick embryos (39).  
 
2.1.6! Transcription Factors  
Transcription factors are proteins that help regulate the transcription of DNA to RNA. As 
a result, transcription factors play a critical role in the regulation of RNA and ultimately protein 
expression. Three transcription factors have been identified to affect tendon development: 
scleraxis (Scx), Mohawk (Mkx), and early growth response 1 (Egr1).  
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2.1.6.1!Scleraxis 
Scleraxis is known as a basic helix-loop-helix (bHLH) transcription factor due to its protein 
structure, which consists of two alpha helices connected by a short loop. It is currently the most 
distinctive and earliest marker for tendon progenitor cells (41). Scleraxis was first discovered 
within mesenchymal cell lineages that give rise to connective tissues and found to be specific to 
tendons and ligaments (39, 42). Schweitzer et al. found scleraxis to be induced by signals from the 
ectoderm and restricted with BMP signaling. Though scleraxis appears to affect both cellular 
differentiation and ECM regulation (41) of tendon, removal of scleraxis does not result in the 
disappearance of tendons. Scx-/- mutant mice were viable albeit with severe tendon defects in force-
transmitting and intermuscular tendons, suggesting other regulatory factors (43).     
 
2.1.6.2!Mohawk 
The Mohawk (Mkx) gene is part of the homeobox gene family, which include a large family 
of genes known to direct regulation of anatomical patterns and morphogenesis during embryonic 
development. A study examining Mkx null mice found that mice had hypoplastic tendons with 
reduced fiber diameters. Mice expressed scleraxis and the number of tendon cells remained the 
same as wild type mice, however there was a significant reduction in tendon mass. This suggests 
Mohawk may be related to tendon maturation and plays a significant role in the regulation of type 
1 collagen formation in tendon cells (44). Studies looking into overexpression of Mkx in 
mesenchymal stem cells showed an increase of tendon-related markers and increased collagen 
fiber diameter (45, 46).  
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2.1.6.3!Early Growth Response  
The early growth response (EGR) transcription factors have been also been linked to 
tendon development to some extent. Mutant mice without EGR do not display abnormal tendon 
morphology, but have decreased expression of scleraxis and collagen I (47). Null mice with 
Achilles tendon injuries showed decreased expression of EGR-1, scleraxis, and collagen, one 
week after injury, whereas wild type mice showed dramatic increase in the same markers. This 
suggests EGR-1 may be involved in tendon healing (48) . 
 
 
2.1.7! Growth Factors  
Other regulatory factors identified in tendon regulation include growth factors, such as 
aforementioned TGF-!, FGF, GDF, as well as number of other growth factors such as insulin-like 
growth factor (IGF) and platelet derived growth factor (PDGF). Growth factors can be defined as 
“signal molecules that are involved in the control of cell growth and differentiation” (49). Growth 
factors, which are naturally occurring cytokines, have been shown to be upregulated during 
development and healing and play vital roles in cellular proliferation, vascularization and protein 
synthesis.  
Growth factors that have been associated with increased cellular proliferation include 
epidermal growth factor (EGF), PDGF, and IGF (50-53). It is believed that the increase in cell 
proliferation results in increased collagen production, leading to more robust tendon healing. 
Discovery of new members of the TGF-! superfamily from the work of Storm et al. revealed GDF-
5, 6, 7 (BMP 14, 13, 12, respectively) (54). Though initially thought to be involved in bone and 
cartilage development, the work of Wolfman et al. showed the induction of ectopic connective 
 18 
tissue with the GDF growth factors (55). Since then various studies have looked at the effects of 
GDF on tendon differentiation (56, 57). 
The suppression of growth factors is an alternate strategy in tissue engineering. The presence 
of growth factors during the inflammatory stage of healing, indicate the possible link between 
growth factors and scar tissue development. For example, the presence of TGF-!1 has been 
associated with increased scar formation and adhesions. The suppression of TGF-!1 resulted in 
increased range of motion in rabbits (58). 
Though growth factors have been shown to be potent inducers of tendon differentiation, 
challenges associated with short biological half-life, high required effective doses, high costs and 
difficulty obtaining FDA approval, limit their clinical use (59).  
 
2.1.8!  Challenges of Tendon Tissue Engineering  
Due to the limited current understanding of tendon biology and development, tendon tissue 
engineering also remains at an infant stage when compared to other musculoskeletal systems. 
Unlike other musculoskeletal tissues such as bone or cartilage, much of the tendon differentiation 
process remains undefined. As a consequence, there in a lack of standardized differentiation media, 
as well as a lack of standardized methods to assess tendon differentiation. Ongoing research in 
normal tendon development, as well as tendon pathology, will continue to improve our 
understanding of tendon tissue and help to develop new tendon tissue engineering strategies.  
Another remaining challenge for tendon tissue engineering is the development of 
appropriate animal models and translation to clinical practice. Current animal models involve an 
acute injury followed by immediate repair. The current models in no way reflect chronic 
degenerative tendon injuries or their conditions. Thus, better animal models that can translate 
results from small animal to larger animal models will generate more clinically relevant data (60).  
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Chapter 2: Specific Aims 
1! Objectives/Rationale 
Tendons, as part of the human musculoskeletal system, help actuate movement through 
coordinated efforts between muscles and bones.  The elastic properties of tendons allow them to 
mediate stress concentrations and act as buffer zones between soft and hard tissue. Any disturbance 
to the system can cause debilitating pain and loss of function. Tendon injuries are common with 
roughly 200,000 surgeries, with roughly 4.1 million physician visits attributed to rotator cuff 
injuries alone (61).  
With the increasing rise in musculoskeletal injuries, new treatments must address the 
problems of current strategies with use of allografts and autografts. Tendon injuries cause the 
afflicted time away from work, decreased productivity and increases the economic health burden. 
Tissue engineering has emerged as a feasible approach to develop modern treatments for tendon 
injuries. Though the use of growth factors in tissue engineering is heavily research, commercial 
use of growth factors has not widely matriculated due in part to the low half-life and high costs. 
The high costs and instability of growth factors have prompted research towards growth factor 
alternatives, such as small molecules and other proteins (62).  
The 1980s saw the production of recombinant human insulin, which made it easier and 
cheaper to mass produce insulin (63). Since then, insulin has been structurally characterized and 
though its most popular use continues to be for the treatment of type I diabetes, interests into other 
uses of insulin have grown. The discovery of insulin homologues, later named insulin-like growth 
factor (IGF) I and II, which were observed to stimulate cell proliferation and growth, ignited 
research in areas comparing the two molecules and into non metabolic functions of insulin (64, 
65).  Today, IGF is used in tissue engineering as a growth factor supplement to enhance 
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proliferation and differentiation of cells (51, 52). An alternative approach is to use commercially 
available insulin protein. Due to the homology of IGF and insulin, we propose insulin as a possible 
biological factor for tendon tissue engineering. 
We aim to study the potential use of insulin protein towards tendon tissue engineering and 
to develop an insulin and cell delivery device to help improve and accelerate tendon healing and 
regeneration. The use of insulin to elicit tenogenic differentiation presents a more applicable use 
in a clinical setting than other biochemical factors, as it is widely available and has FDA clearance 
for other medical applications. If successful, the engineered scaffold can be used as a platform for 
other soft tissue engineering applications.   
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2! Selected Preliminary Data   
2.1!Bolus Studies  
Cells were seeded on PCL electropsun fibers and treated for 24 hours in insulin containing 
media at various concentrations (0, 0.01, 0.1, or 1nM). After 24 hours of treatment, treatment 
media was removed and replaced with basal media for the remaining of the study. At later time 
points, groups treated with higher concentrations of insulin had lower rate of proliferation (Fig. 
1A), which may indicate for cells to be in a differentiation state, rather than a proliferative state 
[insert reference]. When the same groups were investigated for gene expression of tendon markers, 
such as collagen I, collagen III, scleraxis, and tenomodulin, higher expression was found with cells 
treated with 1nM of insulin (Fig.1B). When immunostained for collagen I and actin filaments, 
cells grown with 1nM insulin showed higher collagen formation and more organized ECM 
(Fig.1C).  
2.2!Continuous Treatment Studies in Low Serum 
The effect of continuous treatment with insulin was also evaluated on cells grown on PCL 
electrospun nanofibers. To remove the effect of interference from the serum, low serum conditions 
were used. In the presence of low serum, cell have compromised proliferation, as seen in Fig.2A. 
Cell numbers drop and remain stagnant from day 3 to day 14. However, cells treated with insulin 
20 or 250ng/ml of insulin had increased proliferation by day 14. Thus, in the presence of low serum 
conditions, insulin may have a healing effect on cell growth. Gene analysis comparing cells grown 
in low and normal serum conditions, showed higher expression of tendon ECM markers, tenascin 
C and decorin, with cells grown with low serum (Fig 2). However, lower expression of collagen 
in observed in cells treated in low serum. The lack of nutrients may be contributing to a less robust 
growth of collagen I. Higher level of serum may be needed for collagen growth.  
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Figure 2.1. Cells were treated with varying concentrations of insulin. A) DNA content was 
measured indicating lower proliferation at later time points with groups treated with higher 
concentration of insulin. B) Gene expression of tendon markers showed increased expression 
with cells treated with 1nM insulin. C) Cells were stained for col I, actin and nuclei stain. 
Cells treated with 1nM insulin showed greater ECM organization.  
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Figure 2.2. A) Proliferation of cells continuously treated with insulin in low serum conditions 
had higher rates than the control groups at later time points. B) Gene expression of cells 
treated with control base media or with 20ng/ml (3.4nM) insulin in 1% or 10% serum. Cells 
treated with 1% serum showed equal or higher expression of ECM markers, TNC and DCN 
when compared to cells treated with 10% FBS. Addition of insulin increased expression. 
However, low serum conditions showed compromised expression of collagen I.  
 
2.3!Insulin effect on tenocytes 
To gain insight on the possible effects of delivered insulin on existing tendon cell 
populations, rat tenocytes were continuously treated with IGF-1 or insulin in media. In the low 
serum conditions, cells treated with IGF-1 or insulin had higher proliferation at day 10 than cells 
grown with basal media in low and normal serum conditions. These cells showed very high 
B 
A 
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expression of collagen I and mature tendon marker in low serum conditions when compared to 
basal media in normal conditions. Moreover, cells with IGF-1 or insulin treatment showed 
significantly higher collagen I expression. This was corroborated with confocal images of collagen 
immunostaining (Fig.3). 
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Figure 2.3. Continuous Treatment of insulin and IGF on rat tenocytes. A) Proliferation of 
cells treated continuously with insulin or IGF in low serum conditions compared to cells 
treated with normal or low serum controls. B) Expression of tendon markers of cells grown 
in low serum conditions with basal, IGF or insulin. Fold change is normalized to basal media 
with normal conditions with 10% FBS. C) Collagen I and nuclei staining of cells on scaffold 
with basal (left), IGF (middle), or insulin (right) treatment. 
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2.4!Scaffold Conjugation and Bioactivity Studies  
 
Insulin was then conjugated to CA/PCL fibers (Fig.4A) using carbodiimide conjugation. 
To confirm conjugation, insulin-FITC was conjugated to the fibers and visualized under confocoal 
microscopy. As shown, Fig 4B, fluorescent signal if found throughout the scaffold and is well 
distributed. At early time point, day 3, there were significantly more cells on the insulin conjugated 
fiber than the control group (Fig.4C). At day 7, higher expressions of scleraxis and collagen I are 
observed on cells grown on the insulin conjugated fibers (Fig 4D). This initial studies show that 
the insulin is remains bioactive after conjugation. However, longer time points will need to be 
evaluated to determine how long this effect last.   
 
 
 
Figure 2.4. Bioactivity of insulin scaffolds tested. A) SEM image of scaffold made from 
CA/PCL blend (3:1). B) Conjugation of FITC-insulin on nanofibers. C) Proliferation of cells 
on control and insulin conjugated fibers. D) Gene expression on control and insulin 
conjugated scaffolds.   
A B C 
D 
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3! Specific Aims and Hypotheses 
 
3.1!Specific Aim I: To evaluate and characterize the efficacy of insulin as a bioactive factor 
in promoting proliferation and tenogenic differentiation. 
 
Rationale: Previous studies have shown the efficacy of IGF-1 in promoting cellular proliferation 
and tendon maturation. Insulin, a homologue of IGF-1, has shown capable of binding to IGF-1 
receptors, and therefore may be a viable alternative as a tendon differentiation factor. A single 
bolus of insulin was shown to increase tendon markers in bone marrow mesenchymal stem 
cells(66).     
Hypothesis: It is hypothesized the addition of insulin in culture media as a single or continuous 
treatment will provide appropriate chemical signals to elicit a tenogenic response. Cells are 
hypothesized to react similarly to cells treated with IGF-1, which have been shown in literature to 
increase cell proliferation and collagen production. 
 
3.2!Specific Aim II: To develop and characterize a novel insulin delivery matrix system for 
tendon regeneration.   
 
Rationale: Electrospun fibers provide the ideal topographic and elastic properties as tendon grafts 
and have been widely used as cell and protein delivery systems.     
Hypothesis: It is hypothesized the electrospun fibers can be used successfully to deliver insulin 
with tunable properties to modulate insulin release. It is also hypothesized that the incorporation 
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of insulin in a polymeric fibrous matrix will promote and induce differentiation of mesenchymal 
stem cells towards a tendon lineage.   
 
3.3!Specific Aim III: To conduct bioactive feasibility assessments of an insulin delivery 
matrix system in combination with bone marrow derived MSCs, in-vivo.   
 
Rationale: The in-vivo model will provide information on the feasibility of insulin in a tendon 
injury model. The effectiveness of a one-time dose and continuous treatment will be assessed based 
on overall morphology and healing response. Moreover, donor cells will be tracked to determine 
if cells are playing a direct role in ECM development.  
Hypothesis: It is hypothesized that the implantation of a bioactive matrix system to augment a 
tendon defect will aid in healing and regeneration of the injured tendon. It is also hypothesized 
that the addition of donor MSCs will further enhance the tendon regeneration process.  
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Chapter 3: Application of Insulin and Insulin-Like Growth Factor-1 in 
Musculoskeletal Tissue Engineering  
1! Introduction  
Since its formal conception in 1988 (67), the field of tissue engineering (TE) continues to 
make advancements towards finding solutions to existing medical dilemmas. The goals of tissue 
engineering aim to enhance the healing and regeneration of lost or damaged tissues and organs 
through the development of biomaterials and incorporation of biological factors such as cells and 
bioactive factors. Amongst these strategies, growth factors have been widely popular owing to the 
discovery of their importance in embryonic development and tissue healing. Various growth 
factors have been utilized to elicit cellular behaviors such as proliferation, migration, and 
differentiation. Insulin-like growth factor-1 (IGF-1) has been extensively researched for its ability 
to encourage cell proliferation, inhibition of cell apoptosis, and anabolic effects on musculoskeletal 
tissues (51, 52, 68-70). Insulin-like growth factor-1 is named as such due its homology to insulin 
protein. The homology between insulin and IGF-1 and their receptors in terms of structural 
composition has motivated various comparative studies (64, 69, 71), which have shown similar 
effects of insulin on tissue growth (72, 73). This review focuses on the function of insulin and IGF-
1 and highlights the current knowledge of their effects on musculoskeletal tissue growth and 
subsequent use in tissue engineering applications.    
 
1.2!Insulin Superfamily 
The insulin superfamily is comprised of insulin, insulin-like growth factors, and the 
relaxin-like family, as listed in Table 1. Insulin like growth factors can further be divided into IGF-
I and IGF-II. The relaxin-like family are also subdivided into H1, H2, H3 relaxin and insulin-like 
peptide 3, 4, 5, and 6 (74). Members of the insulin superfamily are considered an ancient class of 
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proteins and are thought to be highly conserved in unicellular eukaryotes, as well as invertebrates 
such as insects, mollusks, and chordates and vertebrates (75). Gene studies show the insulin gene 
to be highly conserved in all vertebrate species. It is believed insulin and IGF may have been 
derived from a common ancestral insulin type gene that split early on in vertebrate species (76). 
 All members of the insulin superfamily are initially expressed as pre-prohormones, with 
four distinct regions in a continuous chain consisting of a N-terminal signal peptide, B-chain, C-
chain, and C-terminal A-chain. The removal of the signal sequence peptide on the N-terminal, as 
well as the formation of two disulfide bonds between the A and B chains, and a single bond within 
the A chain, signifies the transition from a pre-prohormone to prohormone. In the active hormones, 
with the exception of IGF, the C chain is cleaved off, leaving behind two peptide chains. For 
insulin like growth factors, the active hormone remains as a single peptide chain, as the C-chain is 
preserved. Insulin and the insulin-like growth factors bind and activate tyrosine kinase receptors 
(RTK), whereas the relaxin-like family of proteins bind and activate G-protein coupled- receptors 
(74, 77). The difference in receptor types may indicate the divergent functions between the relaxin-
like proteins and IGF and insulin. Insulin and IGFs play key roles in cell cycle, survival or 
apoptosis, migration, proliferation, differentiation, metabolism, reproduction, and longevity (78), 
whereas the relaxin-like family appear to have a more prominent role in reproduction (79).  
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Table 1. The Insulin Superfamily  
Insulin 
Superfamily 
Subdivision 
Insulin !!Insulin  
Insulin-like growth 
factors  
!!IGF-1 
!!IGF-II 
Relaxin-like family !!Gene 1(H1) relaxin  
!!Gene 2 (H2) relaxin  
!!Gene 3 (H3) relaxin  
!!Insulin-like peptide 3 (Leydig insulin-like peptide; 
relaxin-like factor) 
!!Insulin-like peptide 4 (placentin; early placenta 
insulin-like peptide) 
!!Insulin-like peptide 5 
!!Insulin-like peptide 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. A and B chains of insulin and IGF-1. Boxes indicate identical residues  
 
2! Discovery and Clinical use 
2.1 Discovery of Insulin 
The discovery of insulin in 1922, though somewhat controversial, can be credited to 
Canadian scientists, Banting, Best, Collip, and Macleod. Their research performed at the 
University of Toronto brought about revolutionary treatment for those suffering from diabetes 
mellitus, a condition caused by the body’s inability to regulate glucose levels. At the time, there 
 
 
 32 
was an understanding of an antidiabetic substance produced in the pancreas and though several 
attempts were made by others to create extracts from the pancreas, most resulted in harmful side 
effects, negating any clinical benefits. The University of Toronto team was the first to produce a 
purified extract of what they later termed, insulin, which forever changed the treatment and 
prognosis of diabetic patients. Banting and Macleod were awarded the Nobel Prize in Physiology 
or Medicine in 1923 for their contributions. They later split the award money with Best and Collip. 
Details of the history and drama surrounding the discovery of insulin is given by Rosenfeld in his 
review, Insulin: discovery and controversy  (80).   
 
2.2!Metabolic Insulin Regulation  
Insulin is an anabolic hormone produced in the pancreas and is the main regulator of 
intermediary metabolism through its acute effect in lowering blood glucose levels. Clusters of 
cells, known as islets of Langerhans, contain insulin secreting cells known as !-cells that make up 
approximately 50% of all cells in the islets. Preproinsulin is synthesized in the !-cells of the 
pancreas. Shortly after, preproinsulin is released into the endoplasmic reticulum where it 
undergoes proteolytic enzymatic cleavage into proinsulin. The proinsulin undergoes further 
cleavage to excise the C peptide, producing the mature form of insulin and the free C peptide is 
stored in vesicles in the Golgi apparatus. Human insulin contains 51 amino acids and has a 
molecular mass of 5.808kDa (81, 82). The peptide chains, A and B contain 21 and 30 amino acids, 
respectively.  
The synthesis and secretion of insulin is highly dependent on glucose concentrations. When 
the glucose concentration is zero or less than 1nM, the membrane potentials of beta cells is 
approximately -70mV. At elevated glucose levels (6mM) the membrane undergoes depolarization 
and receives an influx of extracellular calcium. It is believed the influx of intracellular calcium 
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(occurs at potentials above -20mV) triggers the exocytosis of insulin granules, resulting in insulin 
release into the bloodstream (83, 84). The released insulin proteins bind to the extracellular 
domains of insulin receptors on skeletal muscle, as well as adipose and liver cells, triggering a 
signal transduction cascade that results in the uptake of glucose through glucose transporter 
GLUT-4 in fat and muscle cells.  
 
2.3!Insulin in the treatment of Diabetes 
In the early days of insulin production, insulin came from various animal sources such as 
canine, porcine, or bovine (85). Since 1977, with the advancement of biotechnology, the mass 
production of insulin has possible though the use of recombinant technology that allows the 
synthesis of human insulin through bacteria or yeast (82). Additionally, it is also now possible to 
create insulin analogs that have altered physicochemical, biological, and pharmacodynamic 
properties to help better regulate the glucose levels (86). Today, the human insulin market is 
predicted to be worth approximately 43 billion US dollars by the year 2021, according to Zion 
Market Research (https://www.zionmarketresearch.com/news/global-human-insulin-market). The 
demand for insulin and insulin products has been increasing due in part to the increasing number 
of diabetic patients. In 2015, the CDC reported that 9.4% of Americans have diabetes or 
prediabetes, which amounts to 30.3 million cases in the United States alone. The WHO reported 
an 8.5% global increase in the prevalence of diabetes among adults (18 year of age or older) in 
2014, which amounts to 422 million affected people. Diabetes is the major cause of heart disease 
and stroke and is the seventh leading cause of death in the United States (87).  
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2.4!Discovery of IGF 
The insulin-like growth factors were first identified in the latter half of the 20th century, 
decades after the discovery and purification of insulin. Throughout its discovery, IGF-1 has been 
called many things, which is reflective of its various biological activities (88). In 1957, Salmon 
and Daughaday observed that there was an undiscovered factor present in normal serum that 
stimulated the growth of costal cartilage, measured through sulfate uptake. They termed it 
“sulfation factor” (89). A few years later, in 1963 Froesch et al. described non-suppressible insulin-
like activity (NSILA) components that were unaffected by anti-insulin antibodies (90, 91). By 
1972, due to the molecule’s interaction with growth hormone (GH), the molecule was lumped with 
somatomedin, a group of hormones that inhibit and regulate GH  (92). It was not until 1976, when 
the molecule was isolated and identified with structural homology to proinsulin, did the name 
insulin-like growth factor became the standard terminology (93, 94).  
 
2.5!Role of IGF-1 in Development and Growth 
The insulin-like growth factors are essential to embryonic development and growth. IGF-
1 is mainly synthesized and secreted by the liver and can be transported via the endocrine system. 
Local synthesis of IGF-1 has also been observed and also believed to take part in paracrine and 
autocrine signaling. 
Majority of circulatory IGF-1 is bound to IGF binding proteins. The IGF-binding proteins 
(IGF-BP) extend the half-life of IGF-1and modulate its activity, as only free, unbound IGF-1 can 
activate its receptor. There are six IGF-binding proteins that have been identified (94, 95), with 
75-90% of circulatory IGF-1 coupled to IGF-PB3, which forms a large ternary complex. Included 
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in the IGF-1, IGF-BP3 structure is acid labile subunit (ALS) which serves to provide structural 
stability to the unit (96). 
Insulin-like growth factor-1 exists in its active form as single polypeptide chains with 70 
amino acids with a molecular weight of 7.649kDa (94). The peptide chain contains 4 domains B, 
C, A, and D. Domains B and A are structurally analogous to the B and A chains of insulin, with 
50% of matching amino acid sequences, shown in Figure 1. The C-peptide consists of 12 amino 
acids and does not share any homology to the C-peptide of proinsulin, which contains 35 amino 
acids (88). The D-domain is believed to interact with the IGF-binding proteins. Additionally, the 
pre-prohormone structure of IGF-1 contains a fifth domain known as the E-domain, whose 
function remains ambiguous (95).  
Production of IGF-1 in the liver is modulated by growth hormone (GH). Thus GH or GH 
receptor deficiencies often result in compromised IGF production. For example, Laron Syndrome 
(LS) is a congenital condition that is characterized by the inability to produce IGF due to a genetic 
mutation in the GH receptor gene. Newborns with LS are slightly shorter and exhibit retarded 
skeletal maturation and organ growth throughout childhood (94, 97, 98). Further evidence for the 
importance of IGF-1 to normal growth and development is shown through studies with knockout 
mice with deleted IGF-1 or GF receptor gene, which display a 40-45% size reduction compared to 
heathy controls (99). The development of recombinant human IGF-1 has allowed its use for IGF-
1 deficient disorders. In 2005, the US Food and Drug Administration approved the use of 
recombinant human IGF-1 for IGF-1 deficiency due to genetic GH resistance, defects in GH 
signaling pathway, GH receptor defects, or IGF-1 gene defects.     
IGF-1 has also been used as a therapy for insulin resistance and for insulin dependent and 
non-insulin dependent diabetes mellitus with some level of success (100).  However, insulin-like 
 36 
growth factor-1, like other growth factors, have significant drawbacks that limit its use. Systemic 
injection of IGF-1 was used as a possible therapeutic for insulin resistant patients. Patients received 
IGF-1 injections of 120 and 160ug/kg twice a day. However adverse effects such as edema of the 
face and hands, mild weight gain, fatigue, tachycardia and local burning at the injection site, along 
with other negative effects caused the study to prematurely end (101).  
 
3! Homologous receptors and signal transduction  
The insulin receptor (IR) and IGF-1 receptor (IGF-1R) are part of a family of ligand-
activated receptor tyrosine kinases (RTK), a class of transmembrane receptors with intrinsic 
enzymatic activity that regulate cell growth, differentiation and survival. The human genes for 
IGF-1R and IR also show similarities in the size and number of individual exons (102, 103). Insulin 
and IGF-1 have much higher affinities for their respected receptors, however in certain 
circumstances, such in the case of supraphysiological concentrations, have been observed to bind 
to each other’s receptors. Hybrids of IR and IGF-1R have also been documented. Two isoforms of 
the IR have been observed, IR isoform A (IR-A) and IR isoform B (IR-B). Subsequent studies 
showed subtle differences between IR-A and IR-B, specifically with the absence of exon11 in IR-
A, which results in the absence of 12 amino acid residues in the extracellular subunit of IR-A and 
renders a greater affinity of IGF-II to IR-A (104, 105).  
Unlike other RTKs, both the insulin receptor (IR) and IGF-1 receptor (IGF-1R) exists in 
dimeric form in the absence of ligand binding. The IR and IGF-1R contain two extracellular " 
subunits and two transmembrane ! subunits, with each  "  subunit linked to one ! subunit via 
disulfide bonds. The " subunits have a cysteine-rich domain similarly found with members of the 
epidermal growth factor (EGF) (106, 107). Here, IR and IGF-1R have the least homology (48%) 
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giving rise to ligand specificity. The tyrosine kinase domain within the intracellular ! subunits of 
IR and IGF-1R share 84% homology (102, 108).     
Due to the similarity of insulin and IGF-1 and their respective receptors, many have 
investigated their distinct and overlapping functions. Early studies suggested metabolic functions 
mediated through the insulin receptor, whereas growth promoting actions were stimulated via IGF 
receptors (64, 109). However, later studies found cross reactivity of both peptides to the other 
receptors (65) and binding of insulin to IGF-1 receptors to propagate signaling pathways for 
proliferation and collagen formation (71). Moreover, mitotic or growth promoting actions of 
insulin has been observed with certain cells including hepatocytes, endothelial cells (65), muscle 
cells (110), lung fibroblast cells (71), and umbilical cord derived MSCs (70). Likewise, metabolic 
functions of IGF-1 have been observed (111).  
Insulin receptor substrate (IRS) and Shc are two major substrates of IR and IGF-1R (102, 
112). For insulin, the P13K/Akt pathway has been mainly seen as responsible for acute metabolic 
actions. The Ras/ERK pathway is associated with insulin effects on proliferation and 
differentiation through gene transcription regulation (113). Differential roles of IRS and Shc 
proteins have also been found with IGF-1 signaling. Kim et al. observed in neuroblastoma cells 
that activation of Shc resulted in MAP/ERK pathway that resulted in neurite outgrowth, whereas 
activation of P13K via IRS was associated with membrane ruffling and growth cone extension 
(114).  
Adding to the complexity of IR and IGF-1R signaling pathways is the presence of hybrid 
receptors or heterodimers of IR and IGF-1R. IGF was found to have higher ligand affinity to hybrid 
receptors, with no difference between the IR-A or IR-B (115). Other factors that can affect signal 
transduction include number of receptors, receptor distribution, and ligand binding kinetics. For 
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instance, it was observed that insulin analogues had greater mitotic effects than insulin, which was 
correlated to a slower dissociation rate of the ligand (116). More recently, Cai et al. have 
demonstrated specificity of insulin and IGF-1 signaling to be due to differences in the intracellular 
domains of IR and IGF-1R and to some extent, their extracellular domains as well. Using cells that 
express only IR, IGF-1R, or receptors with mutated intracellular or extracellular domains, they 
observed the intracellular domains of IGF-1R coupled more strongly with Shc and genes involved 
with proliferation, whereas IR more strongly coupled with IRS and genes related to metabolic 
pathways. The difference in action was attributed to differences in the juxtamembrane in the 
intracellular domains, specifically at position 973 of IR and 951 in IGF-1R, which greatly affected 
substrate phosphorylation (117).  
 
4! Applications in Musculoskeletal Tissue Engineering  
Insulin-like growth factor-1 has been widely researched for its growth promoting effects. 
Mitotic effects of IGF-1 have been repeatedly reported in various cell types, as well as its anabolic 
effect on tissue extracellular matrix. Comparable studies with insulin resulted in similar results, 
suggesting the potential use of insulin as a IGF-1 growth factor analog. The following sections 
highlight the current understanding on the effects of IGF-1 and insulin on various musculoskeletal 
tissues including bone, cartilage, muscle, and tendon.  
2.1!Bone  
It has been widely accepted that hepatic IGF-1 plays a critical role in skeletal development. 
For example, IGF-1 null mice have significant growth retardation and often do not survive (118). 
Moreover, congenic mice with low serum IGF-1 exhibit reduced trabecular bone density and 
reduced cortical thickness (119). However, findings by Yakar et al. question the role of hepatic 
IGF-1 in postnatal growth and development. Mice with IGF-1 gene deletion only within the liver 
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showed 75 percent reduction in circulating IGF-1, but showed similar body weight, body length, 
and femoral length to normal mice. This implies that growth was mediated by non-hepatic IGF-1 
(120). A later study with mice with 85-90% reduction in circulatory IGF-1 showed reduction in 
linear growth, decrease in mineral density, and decrease in periosteal circumference and cortical 
thickness (121). Thus, it appears that a critical threshold of circulatory IGF-1 is needed to maintain 
normal bone growth.     
As previously mentioned, circulatory IGF-1 is produced by the liver, however the 
expression of IGF-1 and its receptor in majority of cells indicate the presence of 
autocrine/paracrine signaling of IGF-1.  To gain an understanding on the direct effects of IGF-1 
on bone, Zhang et al. studied knockout mice with mutant osteoblasts, missing the IGF-1 receptor 
gene. Compared to normal controls, the mutant mice displayed a decrease in trabecular bone 
volume and connectivity, with significantly lower rates of bone mineralization (122). IGF-1 
concentrations in bone is found to decrease with age, and is also significantly reduced in patients 
with osteoporosis (123). IGF-1 treatment on bone defects of aged rats showed improved 
mineralization and biomechanical properties (124), suggesting the importance of IGF-1 to bone 
health maintenance.    
In recent years, the importance of insulin on bone has also been highlighted.  A growing 
body of evidence shows a relationship between bone remodeling and metabolic homeostasis. Bone 
health of diabetic patients provides some insight. Type I diabetes mellitus patients, characterized 
by the inability to produce insulin, have an increased risk of fractures with low bone mineral 
density (125). Reduced bone formation and bone turnover were found to be associated with type I 
diabetes mellitus (126). On the other hand, type II diabetes mellitus patients who have insulin 
resistance, exhibit normal bone mineral density (127, 128), but still present similar risk of fractures 
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as Type I diabetes mellitus patients (129). It was hypothesized that insulin resistance could cause 
aberration in osteoblastic insulin signaling. This was found to be the case in insulin resistant rats 
who displayed decreased osteoblast proliferation (125, 130).    
Closer examination of the effect of insulin on bone have been studied through cell studies 
involving osteoblast cells.  To elucidate the effect of insulin signaling on bone and to eliminate 
possible confounding effects from IGF-R signaling, Fulzele et al. engineered mutant mice with 
osteoblast cells lacking insulin receptors.  Much like the mutant mice with osteoblast specific IGF-
1 receptor knockout, the insulin receptor mutant mice displayed decreased trabecular bone due to 
failure of osteoblast maturation and decreased bone formation. Additionally, with time the mice 
developed insulin resistance, along with peripheral adiposity. Further examination revealed 
decreased circulating undercarboxylated osteocalcin. Osteocalcin is a factor produced by 
osteoblasts. Prior to secretion, the osteocalcin undergoes carboxylation that endows the molecules 
with a higher affinity for bone matrix. A small percent of the osteocalcin remains 
undercarboxylated and is released into circulation. Treatment with exogenous osteocalcin was 
shown to improve the metabolic conditions of the mutant mice suggesting that insulin signaling in 
osteoblast stimulate osteocalcin production, which in turn can regulate pancreatic insulin secretion 
to control glucose homeostasis (131). Work from Ferron et al. showed that insulin signaling in 
osteoblast is necessary for whole glucose homeostasis through osteocalcin activity (132). 
Interestingly, the disruption of IGF-1 receptor in osteoblast cells enhanced insulin signaling and 
action. It is believed that the normal presence of IGF-1 receptors dampens insulin receptor 
signaling through the formation of heterodimer or hybrid receptors (133).  
Anabolic effects of insulin on bone were demonstrated early on with studies involving bone 
organ culture systems. Studies conducted on fetal rat parietal bones showed increased collagen 
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synthesis (134, 135), as well as increased mineralization and bone matrix formation (136). Direct 
effect of insulin on bone healing have been conducted on rodent and rabbit models. Insulin injected 
locally into the intramedullary cavities of femur fractures in nondiabetic rats, immediately 
following injury, resulted in enhanced healing (137). 
Several scaffolds have been used in combination with IGF-1 or insulin. Meinel et al. 
encapsulated IGF-1 in poly(lactic-co-glycolic) acid (PLGA) microspheres (138). The 
microspheres were later added to alginate hydrogels in combination with tricalciumphosphate for 
use in an in-situ delivery device. The release of IGF-1 remained stable for up to 7 days. Osteoblast-
like cells, MG63 cultured on the IGF-1 loaded hydrogel scaffold showed a 7-fold increase in 
proliferation. Bone marrow stromal cells grown on IGF-1 incorporated mineralized PLGA 
scaffolds also demonstrated enhanced attachment and proliferation (139). Such studies 
demonstrate the mitotic effect of IGF-1 (140).  Srouji and colleagues have researched the use of 
crosslinked gelatin hydrogel to deliver IGF-1 and transforming growth factor-β (TGF-β), alone 
and in combination. When used in a rat tibia injury model, growth factor hydrogels showed 
significantly more bone formation when compared to hydrogel controls (141). Similar findings 
were found when the same hydrogel system was used to heal a rat mandibular bone defect, 
supporting the osteoinductive activity of IGF-1, in combination with TGF-β (142).  
The incorporation of insulin into delivery systems, minimize possible systemic effects of 
free insulin and help to achieve sustained release for bone healing. Gandhi and colleagues 
examined the effects of local insulin delivery on fracture healing. By utilizing diabetic mice, they 
show the presence of an intramedullary insulin delivery device did not affect the systemic glucose 
levels, but did however result in the complete restoration of the cortical bone at 8 weeks. Complete 
bridging of the facture was observed in non-diabetic rats (143). In other another system, insulin 
 42 
was loaded into PLGA nanospheres. The insulin loaded nanospheres were incorporated into a 
nanohydroxyapitite/collagen scaffold and implanted into a critical sized defect in a rabbit mandible 
model. Significantly higher bone formation was observed on insulin loaded scaffolds when 
compared to controls (144).   
 
2.1.1! Cartilage 
Tissue engineering of cartilage is of great interest to researchers due to cartilage’s lack of 
intrinsic ability to heal and regenerate on its own. Degenerative diseases such as osteoarthritis 
(OA), as well as acute trauma can lead to the erosion of joint surfaces and loss of mobility, along 
with debilitating pain.  Insulin-like growth factor-1 has been identified as a key factor in the 
maintenance of articular cartilage. Decline in circulatory IGF-1 has been associated with the 
development of OA (145). Moreover, decreasing response to IGF-1 has also been observed in aged 
and arthritic cartilage (146, 147), thus further exasperating the problem. Insulin-like growth factor 
is known to promote the production of proteoglycans  (148, 149), which allows cartilage ECM to 
withstand high compressive forces. A decline of IGF-1, as well as a lowered response to IGF-1, 
results in lower proteoglycan synthesis and subsequently cartilage degeneration (149). Lower 
responsiveness to IGF-1 may be due to increase production of IGF binding proteins, which act to 
inhibit IGF-1 receptor binding (145).   
Over the years, a number of studies have looked at the effects of insulin on ATDC5 cells, 
a cartilage cell line, derived and isolated from mouse teratocarcinoma AT805 (150-153), often 
used as model for in-vitro chondrocyte research. Initial work carried out by Atsumi and colleagues 
showed that ATDC5 cells treated with insulin responded with increased glycosaminoglycans 
(GAG) formation, which make up proteoglycan structures. Collagen II expression, a characteristic 
differentiation marker of cartilage, was also increased. Insulin concentrations as low as 100ng/ml 
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could elicit GAG formation, but was only significantly increased with a minimum dose of 10µg/ml 
(150). Since that initial study, several studies on the effect of insulin on ATDC5 cells have been 
undertaken. Hidaka et al. showed stimulation with insulin caused activation of the P13k pathway 
and resulted in the increase of collagen II and collagen X gene expression. They argue that the 
high concentration required to elicit a response (10µg/ml) indicates insulin effects may be 
mediated through IGF-1R (152). However, work from Phornphutkul et al. showed that 
concentrations as low as 300ng/ml was adequate to stimulate collagen X expression in ATDC5 
cells. Furthermore, this concentration caused the phosphorylation of IR, but not IGF-1R, indicating 
insulin effects may in fact be mediated by its own receptor (153).  
Kellner et al. were first to assess the in-vitro treatment of primary bovine chondrocytes 
with insulin supplemented media. Treatment with insulin increased growth rate, GAG content and 
lead to a more mature cartilage phenotype compared to the control group (154). Other studies 
confirm insulin to be essential in the in-vitro differentiation of human mesenchymal stem cells 
with a dose dependent effect capping off  at 10µg/ml (73). In fact, insulin is a componenet in 
standardized chondrogenic differentiation media.  
Several insulin delivery systems for chondrogenic regeneration have been investigated. 
Chitosan spheres that were used to encapsulate insulin at 5wt% were able to release approximately 
100ug/ml of insulin throughout 28 days. The chitosan spheres promoted rounded morphology and 
increased GAG on cultured ATDC5 cells (155). Similar findings were found with subcutaneously 
implanted collagen hydrogels with insulin (156), as well as  insulin loaded PLGA microspheres 
(157).    
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4.4! Muscle  
The insulin-like growth factors have been observed to play keys roles in adult skeletal 
muscle regeneration and hypertrophy (158). Such effects are thought to be mediated through IGF 
effects on resident satellite cells, muscle-specific adult stem cells that reside between the basal 
lamina and sarcolemma of skeletal muscle fibers (159, 160). During increased loading or muscle 
injury, satellite cells, which are typically mitotically quiescent, become activated and become 
involved in muscle regeneration. The initial response of satellite cells is to first proliferate, then 
differentiate into myoblasts-like cell, with eventual fusion with existing myofibers or creation of 
new ones (160). IGF-1 has been shown to be involved in both the proliferation and differentiation 
of muscle tissue (158, 161-163).  
Proliferative effect of IGF on satellite cells have been demonstrated from a number of 
researchers including Chakravarthy et al., who investigated the proliferative capacity of satellite 
cells after sessions of muscle immobilization. It was found muscle atrophy resulting from a single 
period of immobilization (10 days), dramatically decreased the proliferative potential of the 
residing satellite cells, which could not be recovered even after 9 weeks. However, cells isolated 
from animals receiving infusion of IGF-1 (1.9µg/day) for 14 days, had significantly higher 
proliferative capacity (164). IGF-1 has also been shown to stimulate muscle growth. Direct local 
infusion of IGF-1 into tibialis anterior muscle of adult rats for 14 days caused a 9% increase in 
muscle mass, as well as increase in muscle protein, when compared to control animals receiving 
saline infusions. Increase in muscle DNA content also occurred suggesting increase in resident 
cell numbers (165). Mechanisms in IGF induced muscle growth may be related to the suppression 
of protein breakdown, or proteolysis (166). 
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Early studies evaluating insulin effects on myoblasts indicate insulin to induce similar 
effects as IGF-1 (167, 168). Though there remains some controversy whether insulin is acting as 
an IGF-1 analog via IGF-1 receptors (169), there are reports that support insulin effects through 
its own cognate receptor (170). Interestingly, a study on muscle specific knockout mice showed 
mice with single receptor deletion, either insulin or IGF-1 receptor, displayed normal glucose 
homeostasis and muscle mass. However, the combined loss of both insulin and IGF-1 receptors, 
resulted in dramatic decrease in muscle mass and fiber size (171). These results suggest muscle 
growth to be mediated by both insulin and IGF-1 receptors and also indicate the insulin effect on 
muscle growth is separate from metabolic processes. It is worth noting that in clinical studies 
examining the effects of systemic insulin on muscle growth, an increase in muscle protein 
synthesis is not observed unless there is an increase in muscle blood flow and amino acid delivery 
and availability (172).  In fact, it has been documented that insulin infusion into circulation lowers 
amino acid levels in the blood (173). Increased muscle protein synthesis is often only seen at 
supraphysiological insulin levels and when given locally.      
Currently, tissue engineering studies looking into the use of insulin towards muscle regeneration 
have been limited. Though insulin effects on myoblasts were earlier demonstrated to induce both 
proliferation and myogenesis, it has not been widely applied in tissue engineering applications.  A 
few recent works aim to elucidate the signaling pathways involved in insulin-induced myogenesis. 
Conejo et al. found myogensis induction with insulin on C2C12 cells, a mouse skeletal muscle 
line, to involve the P13k/p70S6-kinase and p38-MAPK pathways, with inhibition of the p44/p42-
MAPK (168). Activation of the P13k pathway by both insulin and IGF-1 are thought stimulate 
growth through suppression of proteolytic activity (174). Other insulin related cell studies in 
muscle have in current years mainly focused on the effects of glucose on muscle growth. In high 
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glucose environments, myogenesis of C2C12 cells was shown to be inhibited, with an increase in 
IGF binding proteins. Use of high insulin concentration resulted in the promotion of myogenesis 
(175). Thus, future work should continue to explore the potential of insulin in muscle regeneration.         
On the other hand, research into IGF-1 in tissue engineering applications is ongoing. For example, 
effect of IGF-1 on smooth muscle tissue has been explored in recent years for applications in 
bladder regenerative therapies. A mutant variant of IGF-1 was created to covalently attach to fibrin. 
The mutant variant IGF-1 was found to have equal bioactivity as wild type IGF-1 and has been 
successfully incorporated into functionalized scaffolds with therapeutic benefits towards bladder 
regeneration  (176, 177).   
 
4.5!Tendon 
Similar to cartilage ECM, tendon tissue is limited in its ability to regenerate due to a low 
number of resident cells, as well as low vascularity.  Insulin like growth factor-1 has been identified 
to be involved in all phases of tendon healing that include inflammatory, proliferative, and 
remodeling stages (178). During the inflammatory stage, RNA and protein levels of IGF-1 are 
upregulated indicating a role of IGF-1 during the early stages of healing (179, 180).  Mitotic effects 
of insulin in tendon cells and tendon animal models have also been well documented (181, 182). 
In a full thickness supraspinatus defect in white rabbits, an increase of IGF-1 was observed on the 
fifth day post-surgery, during the proliferative stage. The growth factor was found present in blood 
cells and vascular endothelial cells near the proximal tendon (183). Insulin-like growth factor-1 
has also been observed to increase collagen synthesis (51, 52, 184). Injection of IGF-1 was shown 
to increase collagen content near local areas within the injection site (52).  
Despite the numerous studies conducted on IGF-1 for tendon applications, there has been 
minimal exploration of insulin towards tendon regeneration.  Mazzocca et al. was the first to 
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investigate the effect of insulin treatment on bone marrow derived mesenchymal stem cells. It was 
shown that following a single bolus dose of insulin, cultured bone marrow derived mesenchymal 
stem cells showed increased phenotypic markers of tendon including increase collagen I, scleraxis, 
tendomodulin, and proteoglycans (66). In ongoing studies, insulin was conjugated to the surface 
of polycaprolactone/cellulose acetate blend fibers. Human mesenchymal stem cells grown on the 
insulin functionalized scaffolds also had increased expression of tendon mRNA. In these studies, 
no significant effect of insulin on proliferation was observed when compared to the control group. 
However, a recent study on insulin on umbilical cord derived mesenchymal stem cells found 
significant proliferation after treatment with insulin, but only at minimal concentrations of 1µg/ml.    
 Tendon tissue engineering presents its own unique challenges compared to other 
musculoskeletal tissues. Currently there does not exist a standardized differentiation media for 
tendon. Additionally, many markers of tendon phenotype development are common to other 
musculoskeletal tissues. For example, collagen I, the main constituent of tendon ECM is 
ubiquitous in bone, while GAG markers such as decorin and aggrecan, are also found in cartilage. 
The lack of unique markers and standardized assay poses challenges for tendon tissue engineering, 
however ongoing research from the fields of developmental biology and advances in biomedical 
science fields will provide better insights into tendon healing and regeneration.    
 
3! Closing remarks   
At its discovery insulin revolutionized the lives of diabetic patients and has played an 
integral part in advancing techniques used in protein characterization. Likewise, the discovery of 
a new insulin-like protein, IGF-1 has contributed greatly to the understanding of growth and 
development. Today, IGF-1, with its mitotic and growth promoting effects, is widely researched 
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in musculoskeletal tissue engineering across all tissues in the field. The influence of growth factors 
on tissue development and healing make them attractive biomolecules to stimulate and 
differentiate cells towards desired lineages. However, the limitations associated with growth 
factors have prompted researchers to look for growth factor alternatives, such as small molecules, 
peptides and other proteins. The analogous structures of insulin and IGF-1, as well the observed 
overlapping effects of insulin, makes insulin an attractive candidate as a substitute for IGF-1. 
   
 
 
4! Specific Aim I: To evaluate and characterize the efficacy of insulin as a bioactive factor 
in promoting proliferation and tenogenic differentiation. 
 
4.1!Materials and Methods 
4.1.1! Cell Studies  
Human mesenchymal stem cells, no more than passage 5, were used to for cell studies. 
Prior to the start of the study, cells were serum starved overnight to sync cells to the same cell 
cycle phase G0. Initially cells were seeded on tissue culture plates to determine the optimal 
concentration of insulin for single or continuous treatment (n=4). Once an optimal concentration 
was determined, cells were seeded on fibrous matrices and treated with the optimal concentration 
of insulin, as a single or continuous treatment.   
 
4.1.2! Scaffold Fabrication 
Electrospun fibers were fabricated using standard electrospinning techniques and 
parameters. Polycaprolactone (Mn~ 80kDa) was used to create electrospun fibers with diameters 
in the range of 1-3µm. A 12% weight/volume of PCL was solubilized in 85:15 ratio of methylene 
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chloride and ethanol. A volume of 8ml of PCL solution was placed into a syringe and electrosupn 
on 10x10cm of foil using the following parameters: flow rate: 2ml/hr, working distance: 1cm/kV, 
voltage: 22kV. The scaffold matrices were dried under vacuum and subsequently cut into 1x1cm 
squares. Prior to cell studies, scaffolds were sterilized via incubation in 70% EtOH and UV 
treatment for 30min on each side.  
 
4.1.3! Proliferation 
Cell proliferation was measured using PicoGreen assay or MTS colometric assay. 
Scaffolds were collected at early time points 6, 12, and 24 hours after seeding and later time points 
at day 3, 7, 14, and 21. At collection, samples (n=4) were washed with PBS and collected into 2ml 
tubes containing 500ul of 1% Triton-x buffer. Samples were stored at -20degC until all samples 
were collected. Samples then underwent three freeze-thaw cycles and vortexed to lyse cells and 
remove DNA content.  
Quant-iT™ PicoGreen® dsDNA Assay kit was purchased from Thermo Fisher Scientific. 
The kit contains a reagent that is an ultrasensitive fluorescent nucleic acid stain, which allows 
quantification of double-stranded DNA (dsDNA) in solution. Fluorescence was measured using a 
plate reader with excitation and emission set to 480nm and 520nm, respectively, and with 
sensitivity set at 65.  A standard using the supplied #DNA was created to correlate fluorescent 
values to known DNA concentrations. Scaffolds containing no cells were used for background and 
their readings were removed from all samples to remove any interference from the scaffold.   
MTS assay was also used to determine metabolic activity as a measure of proliferation for 
short studies. MTS CellTiter 96® AQueous One Solution Cell Proliferation Assay was purchased 
from Promega. The MTS assay is a colorimetric assay that measures cell metabolic activity. The 
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MTS reagent is added directly to the cells. The cells interact with the reagent to by reducing it and 
creating a colored formazan product that can be quantified through absorbance at 490nm. At time 
point, cells were washed with PBS and 100µl of fresh media was added, along with 20µl of MTS 
reagent. Cells were incubated in the cell culture incubator (37degC, 5% CO2) for 2 hours. After 
the incubation period, absorbance was measured at 490nm using a plate reader.    
 
4.1.4! Gene Expression  
4.1.4.1!RNA Extraction  
At specific time points, day 3,7, 14, 21, scaffolds were washed with PBS and placed in 
sterile Eppendorf tubes. A volume of 900µl of TRIzol reagent from Invitrogen was added to the 
tubes and incubated at room temperature for two minutes. TRIzol® is a solution of phenol and 
guanidinium isothiocyanate that serve to denature proteins, while simultaneously stabilizing 
biological material.  A volume of 210µl of chloroform was added to the tubes. The tubes were 
vortexed and later centrifuged at 4degC for 20 minutes at 10,000rpm. The addition of chloroform 
causes phase separation of protein, DNA and RNA. The centrifugation step enhances the 
separation, causing protein to fall to the bottom, DNA to the land on the surface of the protein 
layer and RNA remains in the aqueous phase. The aqueous layer was carefully removed and placed 
into new sterile tubes. The RNA was then subjected to subsequent washing steps for purification. 
An equal volume of isopropanol and the tube was centrifuged for 30 minutes at 10,000rpm at 
4degC. Centrifugation causes the RNA product to precipitate out of solution and form a pellet. The 
lysate was removed and a volume of 500µl of 80% ethanol was added to the tube followed by 
centrifugation at 4degC for 10 minutes at maximum speed. This step was repeated thrice. At the 
last washing, ethanol was removed and the tubes were incubated at room temperature with open 
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lids, to allow all remaining ethanol to evaporate. RNA was then eluted with 20µl of ultrapure 
water. The RNA was quantified using 1µl of RNA solution on a nanodrop reader. The 260/280 
ratio given by the nanodrop indicated quality of the RNA product.          
 
4.1.4.2!Complimentary DNA Synthesis  
The collected RNA was reversed transcribed to complimentary DNA (cDNA) using a 
BioRad iScript cDNA Synthesis Kit. A total of one microgram of RNA was used for cDNA 
conversion. A BioRad CFX96 qPCR machine was used to monitor and implement temperature 
gradients for cDNA synthesis.  
  
4.1.4.3!Qualitative Polymerase Chain Reaction  
To determine the expression of specific tendon related genes Qualitative Polymerase Chain 
Reaction (qPCR) was conducted using SYBR green dye. The fluorescent dye binds double 
stranded DNA by intercalating between base pairs. The fluorescent signal is used to quantify the 
amount of amplified DNA. Primers were designed and ordered through IDT. Primer sequences 
used are listed in Table 1.  
Table 1: Primer Sequences   
Gene Forward Primer (5’-3’) Reverse Primer (5’-3’) 
DCN (185) CGCCTCATCTGAGGGAGCTT  TACTGGACCGGGTTGCTGAA  
TNMD (51) GAA GCG GAA ATG GCA CTG ATG A TGA AGA CCC ACG AAG TAG ATG CCA 
SCX (51) CAG CCC AAA CAG ATC TGC ACC TT CTG TCT TTC TGT CGC GGT CCT T 
COL III (186) GATGTGCAGCTGGCATTCC CCACTGGCCTGATCCATGTAT 
COL I (186) TGGTGCAGCTGGTCTTCCA CACGGACGCCATCTTTGC 
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4.1.4.4!Fold Change Calculations  
To calculate fold change, delta-delta CT method was implemented. Housekeeping gene 
betaActin was used and the control group with no treatment was used for normalization.  
 
4.1.5! Protein Expression  
Total deposited collagen content was measured qualitatively and quantitatively using 
immunofluorescence and PicoSirius Red stain, respectively. Total GAG content was measured 
using dimethylmethylene (DMMB) blue assay.  
 
4.1.5.1!Immunofluorescence 
For immunofluorescence, scaffolds were washed with PBS and fixed with formalin for 15 
minutes at room temperature. Scaffolds were then washed with cold PBS for 5 minutes, twice. 
Scaffolds were permeabilized with 0.25% Triton solution and incubated for 10 minutes. The Triton 
was removed and scaffolds were again washed with cold PBS for 5 minutes. The scaffolds were 
then blocked with 3% BSA for 30 minutes at room temperature. The BSA solution was then 
removed and primary antibody for collagen I (rabbit polyclonal purchased from Abcam) was added 
in 1%BSA solution for 1 hour. The primary antibody was then removed and the scaffold was 
washed thrice in PBS for 5 minutes. Secondary antibody was then added for 40 minutes, followed 
by subsequent PBS washing step, for 5 minutes, thrice. Dapi staining was added prior to viewing. 
All scaffolds were viewed under confocal microscopy.   
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4.1.5.2!PicoSirius Red  
Direct Red 80, purchased from Sigma, was used to create a 1mg/ml PicoSirius Red solution 
in picric acid. Scaffolds were washed with PBS and fixed with 4% formalin for 15 minutes. 
Scaffolds were then washed with PBS, thrice. A volume of 500µl of PicoSirius Red solution was 
added to the scaffolds and allowed to incubate at room temperature for 1 hour. After the incubation 
period, all solution was removed from the scaffolds and the scaffolds were washed with DI water 
until the washing solution remained clear. Apparent stain on the scaffolds were then solubilized 
with 0.01N NaOH and the abosorbance was measured at 550nm.   
 
4.1.5.3!GAG   
GAG content was measured using dimethylmethylene (DMMB) blue assay. At specific 
time points, scaffolds were washed with PBS and placed in tubes. A volume of 500µl of digestion 
buffer was added directly to the scaffolds. Digestion buffer composed of Tris/EDTA buffer, 18.5% 
iodacetamide, 1% pepstatin and proteinase K (1mg/ml). Scaffolds were incubated in digestion 
buffer overnight for at least 16 hours at 56degC. Standard was created using chondroitin sulfate. 
A volume of 50µl of standards and samples was added to 200µl of DMMB solution and absorbance 
was measured at 520nm using a microplate reader.     
 
4.1.6! Statistical Analysis  
All studies were analyzed using ANOVA and Bonfferroni multiple comparisons post-test 
using GraphPad Prism software.  
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4.2!Results  
4.2.1! Proliferation  
 
Figure 3.2. The effect of fetal bovine serum concentrations on cellular proliferation at day 1 
and day 7. 
 
 Cells were treated with varying concentrations of fetal bovine serum to determine the 
optimal concertation to use for further studies. Low serum conditions were desired to decrease 
the likelihood of interference from factors naturally present in the serum. However, if the serum 
conditions are too low, cells may not survive. Thus a minimum serum concentration level was 
needed that maintained cell population. A 2%FBS concentration was chosen to conduct all future 
studies as this was the minimum required to maintain cell population without negative effects or 
heightened response, as shown in Figure 3.2.  
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Figure 3.3. (Top) Proliferation of cells treated with 24 hours of treatment, evaluated at 6,12, 
and 24 hours during treatment. (Bottom) Proliferation of cells treated continuously with 
insulin, evaluated at day 3, day 7 and day 14. No significant differences were found between 
insulin treatment groups and control group.  
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Figure 3.4. Metabolic activity of insulin treated cells after 24 hours at higher concentrations 
using MTS assay. (* p<0.05, **p<0.01, ***p<0.001). 
 
Cells were cultured on electrospun PCL fibers and treated with DMEM media containing 
various concentrations of insulin and 1% penicillin/streptomycin. Cells were collected after 6, 12 
and 24 hours in treatment (n=6). To determine long term effects of insulin on proliferation, cells 
were grown on electrospun PCL scaffolds (n=6) and treated continuously with various 
concentrations of insulin. DNA was collected at day 3, day 7 and day 14. There was no statistical 
difference between any of the treatment groups and the control group within the first 24 hours of 
treatment and subsequent days following treatment.  
 To determine if higher concentrations of insulin would have on effect on proliferation of 
human mesenchymal stem cells, cells were treated with higher concentrations of insulin 
supplemented on tissue culture plate and evaluated for metabolic activity after 24 hours. Metabolic 
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activity of cells treated with 1µg/ml insulin supplemented media or higher, showed significantly 
higher metabolic activity after 24 hours when compared to the control.   
 
4.2.2! Single Bolus Gene Studies  
 
 
Figure 3.5. Gene expression of cells treated with a single 24-hour treatment of insulin and 
evaluated at day 7 and 14. Cells treated with 10ng/ml had significant increase in gene 
expression of all markers tested compared to the control group (* p<0.05, **p<0.01, 
***p<0.001, statistically significant from basal control group; # p<0.05, ##p<0.01, 
###p<0.001, statistically significant from indicated group). 
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Cells grown on TCP received a single dose of insulin of varying concentrations for 24 
hours. After 24 hours, the insulin medium was removed and changed to basal medium. After 7 and 
14 days, post treatment, RNA was collected from the samples (n=6) and evaluated for tendon gene 
expression, shown in Figure 3.6. Cells treated with 10ng/ml (1.7nM) of insulin had the highest 
expression of the markers evaluated, scx, tnmd, col I, col III, and dcn and were statistically 
significant from the control group at day 7. Cells treated with 100ng/ml and above had increased 
expression of col I, col III and dcn at day 7. At day 14, there was an overall decrease in the 
expression of markers when compared to day 7.  
 
Figure 3.6. Gene expression of cells treated with single bolus treatment of 10ng/ml of insulin 
compared to cells treated with single dose treatment of 250ng/ml IGF-1 (* p<0.05, **p<0.01, 
***p<0.001, statistically significant from basal control group; # p<0.05, ##p<0.01, 
###p<0.001, statistically significant from indicated group). 
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To evaluate comparison to IGF-1, cells were grown on electrospun PCL fibers and received 
a single bolus treatment of 10ng/ml insulin, 250ng/ml IGF-1, or control medium. Gene expression 
was evaluated at day 3, 7, 14, and 21. Cells treated with insulin peaked significantly at day 7 for 
scx, col I and dcn. At day 3 and later time points, cells treated with a single 24-hour treatment of 
insulin were not statistically significant from the control group. Cells treated with single 24-hour 
treatment of IGF-1 had significant expression of scx at day 3, tnmd at day 21, and col III at day 3. 
In general, at later time points, day 14 and 21, expression of markers was decreased, with the 
exception of tnmd, which peaked at day 21 for both insulin and IGF-1 treated groups.   
 
4.2.3! Continuous Gene Studies  
 
Figure 3.7. Cells continuously treated with insulin and evaluated at day 7 and day 14, (* 
p<0.05, **p<0.01, ***p<0.001, statistically significant from basal control group; # p<0.05, 
##p<0.01, ###p<0.001, statistically significant from indicated group). 
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In a separate study, cells were treated with various concentrations of insulin supplemented 
media up to 14 days. In general, cells treated with 50ng/ml insulin or below, had decreased 
expression of markers by day 14. However, cells treated with 100ng/ml or 200ng/ml insulin had 
increased or maintained elevated expression of markers by day 14. At day 14, there is a dose 
dependent expression of scleraxis, as well as collagen I.  
 
4.2.4! Comparison to IGF-1 
 
Figure 3.8. Gene expression of cells treated continuously with 100ng/ml of insulin compared 
to cells treated 250ng/ml IGF-1 (* p<0.05, **p<0.01, ***p<0.001, statistically significant from 
basal control group; # p<0.05, ##p<0.01, ###p<0.001, statistically significant from indicated 
group). 
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A concentration of 100ng/ml was chosen to evaluate the temporal expression of continuous 
treatment of insulin since this was the minimal concentration required to maintain expression after 
7 days. Samples were compared to 250ng/ml of IGF-1.  With continuous treatment, there was no 
significant increase in scx expression on any days for both insulin and IGF-1 treated cells. Gene 
expression of col I and III were upregulated for both groups at all time points, peaking significantly 
higher on day 7 for both treatments. Decorin was slightly upregulated, but was not significantly 
higher than controls for both groups, except for IGF-1 treated groups on day 7.  
 
4.2.5! Collagen and Glycosaminoglycan content  
 
   
Figure 3.9. (Left) Collagen deposited on nanofiber scaffolds at day 21. No significant 
differences between any of the treatment groups with the basal control group. (Right) GAG 
content on nanofiber scaffolds collected at day 21. Groups treated continuously with IGF-1 
or insulin had statistically significant increase in GAG content than cells treated with the 
basal control medium or cells treated with a one-time dose of IGF-1 or insulin. (* p<0.05, 
**p<0.01, ***p<0.001, statistically significant from basal control group). 
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Collagen and glycosaminoglycans deposited on nanofibers after 21 days, were evaluated 
from cells treated with one-time dose of insulin or IGF-1 or continuous treatment of insulin or 
IGF-1. There was no difference amongst the groups in collagen content, however cells treated 
continuously with IGF-1 or insulin showed significantly higher GAG content than cells with single 
dose treatment or control medium. At earlier time points, there were no significant differences 
between groups (data no shown).  
  
5! Discussion 
IGF-1 is shown to be upregulated during tissue development and healing and plays a role 
in proliferation and collagen synthesis (51, 181). Various studies show the benefits of IGF-1 in 
healing and tissue engineering applications, however, the high costs and associated complications 
with achieving FDA approval of growth factors has prompted an interest in finding growth factor 
alternatives. Insulin protein is analogous in structure to IGF-1, but is more readily accessible at 
lower costs. The discovery of insulin like growth factors prompted interested research in the 
overlapping functions of insulin. Several studies have shown the potential of either factor to bind 
to the other’s receptors when present above physiological conditions in endothelial (65) and 
fibroblasts cells (71).  
The use of insulin as a bioactive factor in tissue engineering applications has previously 
been researched for chondrogenic differentiation. The potential use of insulin in tendon healing 
applications was first demonstrated by Mazzocca et al.(66). Mazzocca et. al. showed that a 
monolayer of MSCs exposed to a single bolus dose of insulin for 24 hours showed characteristics 
of tendon cells (66). Bone marrow derived MSCs treated with 0.1nM insulin for 24 hours had 
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increased gene expression and protein levels of tendon related markers. A single treatment 
application was emphasized for clinical relevancy, as treatment would be given concurrently 
during the time of surgery. This work further explored the use of insulin for tendon applications 
with MSCs grown on electrospun matrices. In a clinical setting, matrices can act as cell and 
biofactor delivery devices to maintain cells and treatments at targeted areas. 
The use of low serum conditions in the study may have had a profound effect on the insulin 
concentrations required for proliferation and differentiation.  Low serum was used to decrease 
possible interaction from growth factors naturally present in the media. Herchenhan et al., found 
the effect of IGF-1 to be greater in low serum conditions using 0.5% FBS. Additionally, 
preliminary data showed higher expression of tendon markers from samples treated with low 
serum. A concentration of 2% FBS was chosen for this study, as this allowed maintenance of cells 
without drastic decrease in cell population by day 7. Our studies suggest no effect of insulin on 
cell proliferation. Though some studies have found insulin to have mitotic effect on ATDC5 cells  
(72) and smooth muscle cells (110), others have not (155). Mitotic effects from insulin are more 
greatly associated with differentiated cells, whereas this effect does not seem to hold for stem cells. 
As there is the high likelihood that the effect of insulin may be cell dependent, it is difficult to 
assess whether greater insulin concentrations are needed to induce mitotic effects on MSCs. 
Additionally, due to the no serum conditions used during the 24-hour study, and low serum 
conditions during the weekly study, it may be that cells were nutrient deprived with minimal 
metabolic energy that was not adequate for proliferation. Conversely, cells may have been 
expending their energy towards differentiation, rather than proliferation. Moreover, increasing the 
insulin dosage may alternatively foster chondrogenic differentiation rather than tendon 
differentiation.  
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Insulin effect on proliferation was measured using DNA concentration collected from 
scaffolds at 6,12, and 24 hours and 3,7, and 14 days after cell seeding. All groups had slight 
increase in DNA content over time despite the low serum condition (Figure 1A).  A 2% FBS 
concentration was previously found to maintain cell populations without dramatic increase or 
decrease in cell population (Figure S1). No significant differences were found in cell proliferation 
among cells treated with or without insulin supplemented media on PCL scaffolds at 
concentrations up to 200ng/ml insulin. The data suggests, in the presence of low serum conditions, 
at the concentrations tested, insulin did not have an effect on the proliferation rate. Mitotic effects 
of insulin appear to be highly dependent on cell type. Human lung fibroblast cells showed 
significant increase in proliferation after 24 hours post treatment with 2µg/ml insulin (71). In 
human hepatic stellate cells, significant increase in proliferation was observed with concentrations 
as low as 1nM insulin (~ 5.81ng/ml) (69). Insulin treatment on human umbilical cord matrix 
derived mesenchymal stem cells showed no effect on proliferation at insulin concentrations below 
1µM (~5.81µg/ml), but significant increase in proliferation with concentrations above 2.5µM 
(~14.5µg/ml) (70).  
To determine if higher insulin concentrations was needed to induce proliferative effect on 
human bone marrow derived mesenchymal stem cells, metabolic activity of cells grown on tissue 
culture plate was measured after 24 hours of treatment. Our findings showed significant increase 
in metabolic activity with cells treated with concentrations of 1ug/ml insulin or higher (Figure 1B). 
This corroborates with the findings of Li et. al. who observed increased proliferation in umbilical 
cord matrix derived mesenchymal stem cells. The concentration of insulin needed to stimulate 
proliferation may depend on the number of insulin receptors present on the cell. If there are lower 
number of insulin receptors present in the cell, higher dose of insulin may be needed to elicit a 
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proliferative effect (70). No studies to our knowledge have been conducted on the abundance of 
insulin or IGF-1 receptors on human mesenchymal stem cells. Though proliferation was observed 
at higher concentrations, microgram concentrations of insulin was not explored further as these 
concentrations levels have been shown to induce cartilage differentiation. 
Our dose response studies for bolus treatment showed that a concentrations of 10ng/ml 
insulin was optimal for gene expression of tendon markers, which is greater than what was 
previously found. The increase in insulin concentration may have been required to overcome the 
low serum conditions used in these studies. The decreasing expression of tendon markers from 
both insulin and IGF-1 treated cells suggest that the effects of a single bolus treatment may become 
attenuated over time. Whether or not the earlier elevated expression of markers is enough to induce 
cytokine activity and improve tendon healing in an in-vivo model will need to be assessed.  
Based on the dose dependent studies, a concentration of 100ng/ml insulin was chosen for 
the continuous treatment of insulin as this concentration was found to be the minimum required to 
increase collagen I after 14 days. When compared to continuous treatment with IGF-1, there were 
no major differences. However, when compared to the bolus study, it is apparent that continuous 
treatment of insulin was better in maintaining expression of tendon markers beyond day 7. This is 
supported with the GAG content data that showed significantly higher expression from cells 
treated continuously with insulin or IGF-1 than cells treated with control or one-time dose. There 
was no significant difference in collagen formation on the scaffold amongst the groups. When 
deposited collagen was quantified using Sirius red, there were no statistical differences between 
treatment groups.  
From Aim I, it was shown that a bolus single dose of 10ng/ml given for 24 hours was able 
to increase expression of tendon markers, whereas continuous treatment of insulin increased GAG 
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formation. Glycosaminoglycans play a significant role in resisting tendon compression through 
their hydrophilic properties. In addition, proteoglycans, which GAGs are attached to, play a role 
in regulating tendon ECM in terms of regulating fiber diameter and subsequently mechanical 
properties. The upregulation of tendon markers and increased GAG formation are promising 
results supporting the use of insulin as a bioactive factor to promote tendon healing and 
regeneration.   
Insulin’s potential as a differentiation factor has been widely explored for cartilage 
applications (72, 154-157), with only one known publication in the area of tendon regeneration, as 
previously descried (66). However, insulin’s analogue IGF-1 has been widely researched for 
tendon regeneration (51, 52, 184) and shown to increase collagen production (69), the main 
constituent of tendon extracellular matrix (ECM). For this reason, insulin may have potential in 
tendon tissue engineering. Dose studies with cells seeded on tissue culture plates, showed higher 
expression of tendon markers with cells treated with insulin supplemented media when compared 
to the control group (Figure 2). Scleraxis, a transcription factor that is highly expressed by tendon 
progenitor cells (39, 42) at early time points, was significantly upregulated at day 7 for cells treated 
with insulin concentrations equal to and above 10ng/ml insulin. A dose dependent expression of 
scleraxis was found at day 14, with 100ng/ml (p≤0.01) and 200ng/ml (p≤0.001) insulin treated 
groups maintaining significant upregulation. Expression of collagen I was also dose dependent and 
significant increase was observed with cells treated with 100ng/ml insulin and 200 ng/ml 
concentrations at day 7 (p≤0.05) and day 14 (p≤0.001). No dose dependent pattern was found in 
the expression of ECM markers, collagen III and decorin.  Tenomodulin, a mature marker for 
tendon (187), was found to be significantly increased at day 14 with cells treated with 200ng/ml 
insulin (p≤0.01). Since cells treated with 100ng/ml and 200ng/ml insulin tended to have the highest 
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expression of markers, with no statistical difference between the two, 100ng/ml insulin 
concentration was chosen as the optimal concentration to move forward in testing with cells on 
electrospun fibers.  
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Chapter 4: Developing the Extracellular Matrix 
1 Introduction  
All cells of connective tissue reside in an extracellular matrix (ECM) composed of fibers and 
ground substance. It is this extracellular matrix that provides a framework or scaffold which 
provides structural support to the cells that dwell in it. The importance of the ECM in the growth 
and development of cells, have inspired many tissue engineering scientists to mimic the natural 
ECM in fabricating tissue engineering scaffolds. The following sections highlight the fabrication 
methods of tendon scaffolds, materials used, and the dual function of scaffolds to serve as drug 
delivery devices. Further, these strategies are presented in relation to the delivery of insulin for 
tendon tissue engineering.     
 
1.1! Mimicking the Extracellular Matrix 
The extracellular matrix of tendon cells is composed of cells, collagen fibers and the ground 
substance which contains proteoglycans, as previously described in Chapter 1. Several strategies 
have been taken to mimic the natural environment of tenocytes, including the use of collagen based 
scaffolds, the use of nano- and microfibers sheets, and the use of decellularized ECM. 
Biodegradable materials are employed as tissue engineering scaffolds to provide an initial template 
for cells, with the hope that as the scaffold degrades, it will be replaced by the regenerate tissue. 
As such, tissue engineering scaffolds must support cellular attachment, proliferation and 
differentiation. The chemical, physical, and biological properties of the scaffold all contribute to 
overall effect of the scaffold on cell behavior. Considerations for tissue engineering scaffold 
materials and design include 1) biocompatibility with nontoxic degradation products; 2) adequate 
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porosity for cell infiltration, as well as nutrient and waste transport; 3) mechanical integrity; 4) 
topographical cues (188).     
 
1.2! Biomaterials for scaffolds  
Pertinent to the design of ECM mimicking scaffolds is material selection. The physical 
characteristics of the material determines the biocompatibility of the scaffold, as well as its 
mechanical properties and degradation. Metals, ceramics and polymeric materials are utilized for 
tissue engineering scaffolds, but mostly all tissue engineering scaffolds are made from polymeric 
materials due to their tunable mechanical properties and versatility. Polymers can be divided into 
two class of materials – 1) synthetic materials, which include polyesters based materials and 2) 
naturally derived materials, which includes collagen and other biopolymers, such as 
polysaccharides and silk.   
 
1.2.1! Synthetic Polymers 
Synthetic polymer based materials are commonly used in tissue engineering scaffolds due 
to their versatility and relatively easy manipulation of chemical and physical properties, which can 
be optimized for specific applications (188). Additionally, when compared to natural polymers, 
synthetic polymers have higher degree of processing flexibility, without concerns of 
immunogenicity (188, 189). Synthetic polymers used in tissue engineering include aliphatic 
polyesters, polyanhydrides, polyphosphazenes, and polyurethanes. Since polyesters represent the 
most widely used materials for tissue engineering scaffolds, they are reviewed in the following 
sections.   
 
 70 
1.2.2! Aliphatic Polyesters  
Aliphatic polyesters include polylactide (PLA), polyglycolide (PGA), their copolymer 
poly(lactide-co-glycolide) (PLGA), and polycaprolactone (PCL). These polymers are approved 
for human clinical applications by the Food and Drug Administration (FDA) for particular 
biomedical devices and sutures. Their FDA clearance has contributed to the increased use of these 
materials in tissue engineering applications. Synthesis of aliphatic polyesters can be done through 
polycondensation, ring opening polymerization, or enzymatic polymerization. Degradation of 
these polymers occurs through hydrolytic degradation of the main chain ester bonds. Degradation 
rate is highly dependent on the polymer characteristics such as crystallinity, hydrophilicity and 
molecular weight and results in monomers that can be easily metabolized (190). Polymer PLGA 
is one of most popular material for tissue engineering and drug delivery applications. However, 
accumulation of PLGA’s acidic byproducts, lactic acid or glycolic acid, can significantly lower 
the local pH creating a harmful environment for cells and accelerating polymer degradation (191). 
In an experiment comparing identical scaffolds of PLGA and PCL, lower cell viability and 
infiltration were observed on PLGA scaffolds, attributed to the acidic degradation of PLGA (192). 
Another disadvantage for PLGA is its high off-the-self cost. Polycaprolactone represents a slower 
degrading, biodegradable polymer with less economic costs.  
 
1.2.3! Polycaprolactone  
Polycaprolactone is a semi-crystalline polymer with glass transition temperature of 60°C 
and a melting temperature range of 59-64.  It has been used in a variety of scaffold fabrication 
techniques due to its solubility in wide range of solvents and its versatility to be blended with 
various polymers (193). As previously mentioned, PCL possesses slower degradation kinetics 
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when compared to PLA, PGA or PLGA. This has deterred its use, however its slower degradation 
kinetics may be ideal for long term drug delivery applications, as well as regeneration of slower 
growing tissue (194).  
 
Figure 4.1. Synthesis of PCL 
 
1.2.4! Biopolymers  
The desire to mimic and use natural bioinspired patterns and designs have propelled 
scientists to use the natural materials themselves.  One of the main advantages of natural polymers 
over synthetic polymers is their innate biological functions that contribute to overall better 
bioactivity and biocompatibility. The presence of biologically functional moieties allows for 
greater interactions with cells and proteins. Natural polymers can be derived from microbial, 
animal, or plant sources and can be divided into protein-origin polymers and polysaccharides. 
Protein-origin polymers include collagen, gelatin, silk fibroin, elastin and soybean. 
Polysaccharides include chitosan, starch, alginate and cellulose (195). This work involves the use 
of cellulose and thus only cellulose will be reviewed here.  
 
1.2.4.1!Cellulose Acetate 
Cellulose is the most abundant organic biopolymer in the world and is thus readily 
available at low costs. Structural polysaccharides like cellulose are made up of linear chains of 
 72 
monosaccharides linked together by glycosidic bonds. Majority sources of cellulose is derived 
from plants as it is present in plant cell walls, however cellulose can be produced by bacteria, 
algae, and few animal species (196). The structure of cellulose, includes three hydroxyl units per 
glucose molecule, which results in very strong hydrogen bonding between polymer chains or high 
intermolecular forces. Thus cellulose in its native form is insoluble in most solvents. By switching 
the hydroxyl side groups, cellulose derivatives can be synthesized that are easier to process and 
use. Cellulose acetate is a derivative of cellulose which has the hydroxyl groups replaced by acetic 
acid. Cellulose acetate is formed by processing cellulose with acetic anhydride or acetic acid, with 
sulfuric acid as a catalyst. The result is acetic side chain in place of hydroxyl groups. The amount 
of acetic substitution is given by the degree of acetylation. Cellulose acetate is dissolvable, lending 
itself more applicable to scaffold fabrication. The limitations of natural polymers include batch-
to-batch variability and lower versatility in terms of processing.   
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Figure 4.2. Structure of cellulose and its derivative cellulose acetate.    
1.3! Electrospinning 
The electrospinning process is a versatile and simple method to fabricate fibers with 
diameters in the micro- and nanoscale range. In the last two decades, there has been renewed 
interest in the electrospinning process to create nanofibers due to the growing number of 
applications in filtration, protective clothing, tissue engineering scaffolds, and drug delivery 
devices (1). 
Electrospinning involves the use of electrostatic forces to create nanofibers (in the range 
of 100-500 nm, (1). A typical eletrospinning apparatus consist of a collector electrode, source 
electrode, high voltage supply and syringe. The experimental set up is shown in Figure 4.1. A high 
voltage is applied to a polymer solution or melt. The voltage polarizes the charged ions due to the 
electrostatic repulsion between like charges.  In addition, there is an electrostatic attraction 
between the charged liquid and a collector at the other end.  At equilibrium, the surface tension 
and electrostatic forces cause the liquid to form a cone like shaped, known at the “Taylor” cone.  
When the electrostatic forces overcome the surface tension, a jet is emitted from the Taylor cone 
towards the collector.  As it travels the jet decreases in diameter and the solvent is evaporated such 
that a solid fiber is formed and collected at the collector plate (1).  
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Fiber diameter and morphology are the two most important considerations in processing 
nanofibers and are governed by process parameters and solution characteristics.  Process 
parameters include the applied voltage, flow rate, and the distance between the capillary or needle 
and the target collector.  Solution parameters include, but limited to, solution viscosity, which is 
related the solution concentration, and the conductivity of the solution.  In addition, humidity and 
temperature of the surrounding enviroment may also play a role. Much research has been done on 
the effects of these process and solution parameters on fiber diameter and morphology.  
The surface to volume ratio of electrospun scaffolds may have on effect on the overall 
biodegradation of the material when compared to the bulk material. Additionally, lower polymer 
crystallinity has been observed with electrospun scaffolds when compared to films of the same 
material, thus degradation may be accelerated (197). The addition of cells and the interaction 
between cells and the fibers may also contribute to the in-vivo degradation prolife.   
 
 High Voltage source 
Polymer is pushed out 
at a constant rate 
with a syringe pump 
Grounded collector 
catches fibers on 
rotating disc 
Charged polymer undergoes a series of 
instabilities, stretching along the way 
 75 
Figure 4.3. The electrospinning set up involves a syringe pump that pushes the polymer melt 
at a constant rate. A high voltage source attached to the end of the needle opening, charges 
the polymer. When the electrostatic forces overcome the surface tension, polymer is ejected 
from the needle. The electrically charged polymer jet is attracted to the grounded collector. 
On its trajectory to the collector, the polymer undergoes a series of loops and turns, which 
thins out the polymer jet resulting in nanoscale sized fibers.    
 
1.4! Drug delivery and considerations 
Electrospun fibers can also be used to deliver biomolecules such as drugs, growth factors 
and other proteins. The simplest method is direct adsorption of the biomolecule to the surface of 
the scaffold. This method protects the bioactivity of the biomolecule, however interaction between 
the biomolecule and the scaffold relies on relatively weak forces that do not allow for great control 
of release. A burst release is often observed, with most of the biomolecule eluted once the scaffold 
is in a hydrated environment. To gain better control of release kinetics of the biomolecule, it can 
be directly added to the polymer solution prior to electrospinning. Furthermore, the biomolecule 
can be coaxially spun with the polymer, such that the biomolecule is encased in the middle of the 
fiber. Longer release profile can be obtained using these methods, however, the biomolecule is 
subjected to degradation from the solvent in the polymer solution. Direct tethering of the 
biomolecule to the surface of the molecule is another strategy that results in a chemical bond 
between the biomolecule and the surface of the scaffold. Such strategy avoids burst release effects 
and is often conducted in aqueous conditions which do not pose a risk to the bioactivity of the 
biomolecule.     
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2! Specific Aim II: To develop and characterize a novel insulin delivery matrix system 
for tendon regeneration.   
 
2.1! Materials and Methods  
 
2.1.1! Fabrication of Electrospun fibers 
Scaffolds were fabricated using standard electrospinning techniques. Polycaprolactone 
(80,000 Mn) and cellulose acetate (CA) were weighed to create a 12.5 weight/volume percent 
solution in trifluorethanol. The ratio of PCL to cellulose acetate varied from 25, 50, and 75 percent 
CA. Polymer solutions were dissolved overnight at room temperature. Polymer solutions were 
electrospun at 1kv/cm, at a flow rate of 2ml/hour and collected on a grounded plate with a 10x10cm 
foil. Scaffolds were dried and stored under vacuum until use.  
 
2.1.2! Characterization 
2.1.2.1!Fiber Diameter  
Scaffolds were sputter coated with gold/palladium and viewed under SEM at 500x 
magnification. Using Image J software, 50 fibers from 3 images were measured to give an average 
fiber diameter for each polymer composition.  
 
2.1.2.2!Contact Angle   
Contact angle was measured using a goniometer. A drop of water was placed on 1x1cm 
scaffold and the resulting contact angle was recorded. A total of 6 readings were averaged to obtain 
the average contact angle for each polymer composition.   
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2.1.2.3 Tensile Testing  
Tensile mechanical testing was conducted using 10mmX20mm sheets, per ASTM 
standards on an Instron Tensile machine using a 50N load cell. Scaffolds were incubated in PBS 
overnight prior to testing.   
 
2.2! Cellular Attachment  
Scaffolds were cut into 1x1cm squares and were sterilized with immersion in 70% ethanol 
and exposure to UV on each side for 30 min. After sterilization, scaffolds were placed in 48-well 
plate dishes and incubated with standard DMEM cell culture media (10% FBS, 1% 
penicillin/streptomycin) overnight. Human mesenchymal stem cells, in passage 5, were seeded on 
the scaffolds, with an initial seeding density of 30,000. After 24 hours, scaffolds were collected in 
2ml tubes and digested with proteinase K. A volume of 500ul of proteinase K solution was added 
to the scaffolds. The tubes were closed and kept at 56degC water bath for 16 hours. After digestion, 
scaffolds were frozen until assay was performed. Quant-iT™ PicoGreen™ dsDNA Assay Kit was 
used to measure DNA content. Readings from cell-free scaffolds served as scaffold negative 
controls and were subtracted from sample readings.      
 
2.3! Insulin Conjugation 
After sterilization, 1x1cm scaffolds were placed in 24-well plate dishes and treated with 
500mM of sterile NaOH for 1 hour to cleave ester bonds present in PCL. This allowed for free 
carboxyl groups on the scaffolds to partake in conjugation. The scaffolds were then incubated in 
sterile 100mM MES buffer for 1 hour. The MES buffer was removed and fresh MES buffer 
containing coupling reagents EDC/NHS (500ug/ml) and insulin (10ug/ml) was added to the wells. 
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The well plates were wrapped with parafilm and placed on a rocker overnight. After conjugation, 
the MES conjugation buffer was removed and the scaffolds were washed with sterile water 
repeatedly 5x to remove unreacted products.  
 
2.4! Insulin Quantification  
The amount of insulin conjugated on the scaffolds was measured using bicinchoninic acid 
assay (BCA). Scaffold samples were incubated in MES buffer with insulin in the presence or 
absence of crosslinking agents EDC/NHS. Scaffolds in buffer with insulin without crosslinking 
agents gave the amount of insulin directly adsorbed onto the scaffold. This value was then 
subtracted from the total amount of insulin on the scaffold to render the amount of insulin 
chemically conjugated onto the scaffold.    
 
2.5! Cell Studies  
Cells studies were conducted on 1x1cm scaffolds using commercially available bone 
derived human mesenchymal stem cells from Lonza. Scaffolds were sterilized and conjugated as 
previously described. Cells were seeded with an initial seeding density of 50,000/scaffold. Cells 
were treated with DMEM media with low serum (2% FBS) and 1% penicillin/streptomycin. Media 
was exchanged every 2-3 days.      
 
2.6! Proliferation 
At day 3, 7, and 14, scaffolds were washed and collected into 2ml tubes. The tubes were 
frozen until analysis was performed. At the end of the study, all samples were digested with using 
papain digestion. A volume of 500ul of papain digestion buffer was added to the tubes and 
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incubated at 65degC overnight for 16 hours. After digestion, amount of DNA in the lysate was 
measured using Quant-iT™ PicoGreen™ dsDNA Assay. Cell-free scaffolds served as negative 
controls and readings were subtracted from sample values to remove interaction with scaffold 
material.  
 
2.7! Gene Expression  
At day 3, 7, and 14, scaffolds were washed and collected into 2ml tubes. The tubes were 
kept in -80degC until analysis. RNA was extracted using standard Trizol extraction methods. At 
the end of the study, Trizol was added directly to the tubes. The tubes were vortexed and incubated 
at room temperature for 5 minutes. Chloroform was then added to the tube at a ratio of 210:900 of 
chloroform to trizol. The samples were vortexed and centrifuged at 10,000xg for 30 minutes in 
4degC. Centrifugation resulted in phase separation of RNA, DNA and protein. The top aqueous 
layer, which contains the RNA, was carefully pipetted into new autoclaved 2ml tubes. Equal 
volume of isopropanol was added to the RNA lysate and the samples were kept in -80degC 
overnight. The next day, the samples were centrifuged at 10,000xg for 30 minutes in 4degC 
causing the RNA to form a pellet. The tube was carefully decanted and 80% ethanol was added. 
The samples were centrifuged at maximum for 10 minutes in 4degC. The tube was decanted and 
fresh ethanol was added. The samples were centrifuged at maximum for 10 minutes in 4degC. The 
tubes were decanted to remove as much ethanol as possible. The samples were spun down and any 
remaining ethanol was removed using a clean pipette. Care was taken not to disturb the RNA 
pellet. The RNA pellet was then reconstituted in 20ul of water. The RNA was quantified using a 
NanoDrop instrument. A concentration of 1ug of RNA was used to synthesize cDNA using BioRad 
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iScript cDNA synthesis kit. To analyze the presence of tendon related genes, qPCR was conducted 
using BioRad iTaqTM Universal SYBR® Green Supermix.    
 
2.8! DMMB 
Using the same lysate from the papain digestion, amount of glycosaminoglycans (GAG) 
were measured by carrying out dimethylmethylene blue assay (DMMB).  
 
3! Results  
3.1! Material Selection 
Polycaprolactone was chosen as a synthetic polymer for its mechanical strength, however 
due to its high degree of hydrophobicity and subsequent lower interaction with biological material, 
it was blended with natural polymer cellulose acetate (CA). Cellulose acetate is derivative of 
cellulose, one the most abundant natural material on earth. Biological materials have higher degree 
of interaction with CA due to greater hydrophilicity. To assess the optimal polymer composition, 
electrospun fibers were fabricated using the following weight ratios of PCL:CA, 100:0, 75:25, 
50:50, 25:75. All fiber compositions had a polymer weight:volume ratio of 12.5% and were 
dissolved overnight in trifluorethanol. The polymers were electrospun at 1kv/cm, at a flow rate of 
2ml/hour. Fibers were collected on a grounded plate.      
 
3.1.1! Fiber Diameter 
At all polymer concentrations, PCL, 25%CA, 50%CA, and 75%CA, bead-free fibers were 
produced. SEM microscopy was used to measure fiber diameter of the scaffolds. Overall, fiber 
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distributions ranged from nano- to micrometer range. Increasing CA concentration rendered 
decreasing fiber diameters.  
 
3.1.2! Mechanical Properties  
Mechanical testing was conducted using 10mmX20mm sheets, per ASTM standards on the 
Instron Tensile machine with a 50N load cell. Increasing stiffness was observed with increasing 
concentration of CA until 75%CA, where modulus is decreased. Moreover, 75%CA scaffolds had 
the lowest tensile strength, whereas there was no difference between 25%CA and 50%CA. As 
expected, PCL had the highest tensile strength and elasticity.  
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Figure 4.4. SEM images of various compositions. All fiber diameters were statistically 
significant, except for PCL and 50%CA, which were similar in diameter.  
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Figure 4.5. Tensile strength and modulus of the different polymer composition 
 
3.1.3! Water Contact Angle   
The addition of CA did not significantly decrease the water contact angle of nonhydrolyzed 
scaffolds. However, after treatment with 500mM NaOH for 1 hour, water contact angle of all CA 
compositions were not measurable on the goniometer, as water was readily absorbed on the 
material as quickly as the droplet was placed on the sample.  
Table 1: Water contact angle  
 
 
 
 
 
 
 
Scaffold Composition PBS Treatment 
PCL 116˚±9˚ 
75% PCL- 25% CA 114˚±6˚ 
50% PCL- 50% CA 106˚±2˚ 
25% PCL- 75% CA 105˚±1˚ 
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3.1.4! Cellular Attachment  
To assess cellular attachment on the various composition of polymer, human MSCs were seeded 
statically on the fibers. After 24 hours, the scaffolds were collected and DNA was measured 
using PicoGreen Assay kit. All CA scaffold compositions had higher cellular attachment than the 
PCL scaffold after 24 hours. However, increasing CA concentration decreased the number of cell 
attachment.   
 
 
Figure 4.6: DNA concentration on polymer compositions after 24 hours 
 
3.1.5! Protein Immobilization 
Scaffolds were first hydrolyzed in 500mM NaOH in order to cleave ester bonds on PCL 
and create free carboxyl groups on the scaffolds that could participate in amide bonding of insulin 
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onto the surface of the scaffold. The scaffolds were incubated overnight at room temperature in 
MES buffer (100mM) containing the coupling reagents EDC/NHS and insulin-FITC.  
 
 
Figure 4.7. Insulin-FITC was conjugated to fibers and viewed under confocal microscopy.  
 
 
 
PCL 
25%CA 
50%CA 
75%CA 
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Figure 4.8. The amount of insulin immobilized onto the scaffold decreased at higher 
concentrations of cellulose acetate 
 
3.1.6! Biological Assessments 
Cells seeded on insulin functionalized scaffolds showed decreased DNA concentration at 
later time points compared to cells grown on control scaffolds.  
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Figure 4.9 DNA concentration on insulin treated scaffolds and neat scaffolds.  
 
 
Figure 4.10. Insulin released into media 
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Figure 4.11. Gene expression of tendon markers on insulin immobilized scaffolds. Results 
mimic those of cells treated with insulin supplemented media.   
 
 
4! Discussion  
A PCL-CA blend was chosen to combine the advantages of both synthetic and natural 
polymers. Polycaprolactone is widely used in tissue engineering applications mainly due to its 
strong mechanical properties and versatility, as well as its FDA approval in sutures and drug 
delivery systems (198). Moreover, PCL lends itself to be easily blended with other polymers. The 
addition of natural polymers like cellulose acetate have been shown to improve biocompatibility 
(199, 200). In recent years, the global market for cellulose acetate has been rapidly increasing with 
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a predicted value of approximately 7 billion dollars by the year 2021 (201). The relative abundance 
and flexibility has fueled interest in cellulose acetate in a myriad of areas including biomedical 
applications such as tissue engineering and drug delivery (202, 203).  
 SEM images of PCL-CA blend scaffolds showed bead free, continuous fibers (Figure 4A). 
Properties of scaffolds are listed in Supplementary Table 1. With increasing CA concentrations, 
there was a decrease in fiber diameter (Figure 4B). A similar trend was found with PCL-CA blend 
fibers fabricated by Farooq et al. (204). The addition of CA also lowered the tensile strength of the 
scaffolds, with significantly less maximum load associated with the blend fibers (Figure 4C).  
Similarly Bin et al. fabricated electrospun PVA-CA blend scaffolds and found increasing CA 
content in the blend scaffolds decreased overall mechanical strength (205). 
With increasing CA concentrations, the water contact angle was decreased (Figure 4D). 
This was expected as PCL is highly hydrophobic, whereas CA is hydrophilic. Higher DNA 
concentration was found on the blend scaffolds when compared to PCL only group (Figure 4E). 
Significantly higher DNA content was found on the 25%CA group when compared to PCL 
(p<.05). This is attributed to the increase in hydrophilicity of the scaffold, which would have 
allowed for greater cellular attachment.  
There are several methods that can be employed to deliver biomolecules on electrospun 
fibers including physical adsorption, co-electrospinning, and chemical conjugation. Physical 
adsorption, the simplest method, relies on relatively weaker interactions such as electrostatic 
forces, hydrogen bonding and van der Waals interactions that can be difficult to control (206). 
Biomolecules that are added to the polymer solution for co-electrospinning run the risks of 
degradation from solvents used in the solution (207). Chemical conjugation is a much milder 
process that is conducted in aqueous solutions, which helps preserve the bioactivity of the 
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biomolecule. Additionally, chemical conjugation of protein on the surface of scaffolds allows for 
greater control and longer activity of the immobilized biomolecule (206). Cells can directly 
interact with the immobilized insulin and modulate cellular behavior. Thus, chemical conjugation 
was implemented to functionalize the scaffolds with insulin.  
The electrospun fibers were initially hydrolyzed to provide ester groups as sites for 
conjugation of insulin to the fibers. No significant difference was found in the amount of 
immobilized insulin between PCL and 25%CA scaffolds, which measured 67ng and 76ng, of 
insulin per scaffold respectively. However, significantly lower amounts of immobilized insulin 
were measured on 50%CA and 75%CA scaffolds, 26ng and 8ng, respectively. The amount of 
immobilized insulin on the PCL and 25%CA scaffolds are in range with other similar reactions on 
PCL fibers. Yoo et. al observed 49ng of neural growth factor conjugated to PCL/PEG electrospun 
fibers (208), whereas Cheng et. al found 120ng of collagen immobilized on PCL/chitosan fibers 
(207). Based on the findings with regards to tensile strength, cellular attachment, and amount of 
immobilized insulin, the scaffold composition with 25% cellulose acetate was chosen to conduct 
biological feasibility studies.  
Clinically, insulin delivery must be dealt with cautiously as insulin is an important and 
integral part of normal homeostasis. The concentrations tested in these studies are far below the 
international unit of insulin (34.7µg/ IU) and thus are not expected to have systemic effects. 
Moreover, insulin was immobilized onto the scaffold, thus reducing a possible burst release effect. 
Insulin released into the media was measured during the duration of the study. By day 14, roughly 
19% of the insulin was eluted into the media. This demonstrates a slow release of insulin and 
demonstrates the avoidance of a burst release effect commonly associated with biomolecules that 
are physically encapsulated.    
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At day 14, there was significant decrease in DNA content with the insulin conjugated 
scaffolds when compared to the control group (p ≤0.001). This may indicate that cells seeded on 
the insulin conjugated scaffolds are expending energy towards differentiation rather than 
proliferation, as evidence indicates an inverse relationship between the two cellular modalities 
(209). Earlier findings showed no difference in proliferation with cells on PCL scaffolds with 
insulin supplemented media. This may be due to experimental differences. For insulin immobilized 
scaffolds, a lower initial seeding density was used to ensure cells adequate space to proliferate. 
This resulted in overall less DNA content, but a visible and significant increase in DNA 
concentration at day 14 for cells treated on control scaffolds.  
In terms of differentiation markers, there was an upregulation of scleraxis observed at day 
7 (p ≤0.05) with a significant increase in tenomodulin at day 14 (p ≤0.05). When compared to cells 
treated directly with insulin supplemented media, cells grown on insulin immobilized scaffolds 
seem to have a slower progression as evidenced by later increase in tenomodulin at day 14, rather 
than day 7 as was seen with the former. What might account for this difference in the accessibility 
of cells to the insulin protein. Though chemical conjugation of biomolecules onto the surface of 
fibrous scaffolds allow for greater attachment to the fibers, the site of attachment may potentially 
decrease the bioactivity. Due to chemical modification, cells may not recognize the biological 
ligands of the biomolecule, as they may not be fully exposed (206). It is important to note however, 
that cells grown on the insulin immobilized scaffolds still had an upregulation of tendon markers. 
Thus the amount of immobilized insulin on the scaffolds was suffice to increase tendon markers 
and remained bioactive throughout the study.  
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Chapter 5: In-vivo Study of Insulin in Rat Achilles Tendon Defect 
1!  Introduction  
 Tendon injuries account for roughly half of the 33 million musculoskeletal injuries that 
occur annually (5). Treatment for tendon injuries include nonsurgical and surgical treatments, 
however nonsurgical treatments have shown to gain functional recovery in only 60% of cases (26). 
Additionally, 29% of patients seeking nonsurgical treatments eventually receive surgical 
intervention (21, 210, 211). Tendon surgical repairs will vary according to type of tendon rupture, 
however in general, tendons are repaired through debriding the torn area and suturing the tendons 
ends together or back to the insertion site, depending on the location of the tear. In cases where 
there is limited tissue left, grafts can be used to augment the tendon tissue. However, commercially 
available grafts have had variable clinical results (28), calling the need for more effective 
treatments. Tissue engineering has emerged with new solutions to tendon injuries by way of 
scaffolds and biomolecule and cell delivery strategies (212). Testing of tissue engineering 
scaffolds for their biocompatibility and effectiveness are first often conducted in small rodent 
models and rabbits before proceeding to larger animal studies such as ovine. These animal studies 
provide important preclinical data.  
 
1.1! Commercial Grafts 
1.1.1! Biological   
The practice of tendon grafts to augment large tendon defects involves the use of autografts, 
allografts or xenografts. Autografts, taken from another site of the body, is limited in availability 
and requires a secondary site of injury that poses increased risk for complications. Thus, 
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transplantation of allografts and xenografts have gained increased popularity for rotator cuff and 
Achilles tendon repair (28). 
The Graftjacket is a commercially available allograft taken from human cadaver skin. The 
tissue is decellularized using a patented technique that removes epidermal and dermal cells, and 
preserves ECM components such as collagen, elastin, and proteoglycans (213). It has been used 
successfully for skin lesions (214, 215) and abdominal repair (216, 217). Applications for 
Graftjacket in Achilles (218) and rotator cuff repair (219, 220) have also been tested and shown to 
improve clinical outcomes, however retear rates as high as 30% have been found with its use in 
rotator cuff repairs.   
Xenografts, taken from animals, also make up a large portion of available biological grafts. 
Porcine small intestine submucosa (SIS) are the source for the Restore patch, as well as CuffPatch. 
The Restore patch was the first biological scaffold on the market (28) and is composed of ten 
individual layers of porcine SIS.  Approximately 90%  of the Restore patch is made up of collagen 
with the remaining 5-10% made up of lipids, carbohydrates and TGF-!(213, 221, 222), allowing 
it to be marketed as an acellular collagen scaffold with growth factors. Though animal studies 
(223, 224) and some clinical trials (225) showed favorable results with Restore, subsequent studies 
have shown high failure rates and limited success (226, 227). Moreover, Zheng et al. reported the 
presence of multiple layers of porcine cells within the patch (228), highlighting one of the 
limitations associated with biological scaffolds.  
Other biological scaffolds include the Zimmer patch and TissueMend, which are sourced 
from porcine and fetal bovine dermis, respectively. The Zimmer patch, (formally known as 
Permacol) and TissueMend are composed of a single layer of acellular skin graft, composed mainly 
of collagen. Results of clinical trials of the Zimmer patch have been mixed. Some studies showed 
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great improvement was found in pain relief, range of motion and satisfaction in ten patients who 
underwent rotator cuff reconstruction with the Zimmer patch (229, 230). Conflicting results were 
found in another study with four patients who had recurrent tears and decreased range of movement 
after 3-6 months following repair with the Zimmer patch (231). No clinical data has been published 
on the TissueMend for tendon applications (28). 
Due to their inherent biological properties, biological grafts have shown to be highly 
biocompatible. However, risks of disease transmission and rejection due to the presence of foreign 
DNA, requires better processing methods to remove cellular material. Biological grafts are also 
plagued with lower mechanical properties and undefined degradation rates (28). The performance 
of many commercial grafts have been mixed owing to the fact that many studies are retrospective 
without proper controls.           
 
1.1.2! Synthetic Prosthesis  
Synthetic, non-absorbable tendon grafts provide much higher mechanical properties than 
biological grafts, do not carry risks for disease transmission and have tunable material properties. 
Tendon prosthesis made from polyester, polypropylene, polyarylamide, dacron, carbon, silicone, 
and nylon fibers were popular in the 1980s and 1990s, however complications associated with 
biocompatibility have limited their use. The synthetic prosthesis had issues such as implant 
degradation, device failure, severe synovitis and inflammation. Due to these complications, many 
synthetic grafts have since been stopped for use in tendon applications. (28, 232-234). Research 
has now moved towards finding degradable synthetic materials, reviewed in Chapter 4.  
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2! Animal Tendon Model 
In-vivo animal models provide vital information on the performance of scaffolds in a 
biological and dynamic environment that cannot be easily simulated in an in-vitro environment. 
Tendon models for tendon regeneration include the rotator cuff tendons (31, 235, 236) as well as 
the Achilles tendon (179, 237). The tendon model for this work will focus on the rat Achilles 
tendon model.   
The Achilles tendon is one the largest tendons in the body, ranging from 11-26cm long, 
with an average length of 15cm (238). The Achilles is a conjoined tendon that connects the 
gastrocnemius and soleus muscles to the calcaneal tuberosity (239) that aids in walking, running, 
and jumping. The tendon is subjected to high loads reaching as high as 9kN during running 
activities, which equals up to 12.5 times body weight (238, 240). The blood supply of the tendon 
is derived from the musculotendinous and osteotendinous junctions, as well as vessels in the 
surrounding connective tissue, supplied from the posterior tibial artery and peroneal artery, 
respectively. Like most tendons, vascularity to the Achilles tendon is overall low, but the 
midsection of the tendon is marked with relatively higher hypovascularity. As a result, most 
injuries and ruptures occur at the midsection, 2-6cm proximal to the bony insertion (238).   
Tendon ruptures often occur during strenuous physical activities that involve sudden forces 
caused by pivoting or rapid acceleration. In the United States, majority of Achilles injuries (68%) 
are attributed to sport injuries, specifically basketball, tennis, and American football. Middle-aged 
males, described as “weekend warriors,” who occasionally participate in athletic endeavors, were 
shown to have the greatest risk of injury (241). The incidence of Achilles tendon ruptures in North 
America range from 5.5 to 9.9 ruptures per 100,000 people (242).  Surgical treatment of Achilles 
tendon rupture consists of reattaching the tendon ends using nonabsorbable sutures, such as fiber 
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wire, followed by several weeks of immobilization and physical therapy thereafter. In a two year 
follow up, patients repaired tendons were found to be structurally and mechanically different from 
the contralateral uninjured tendon, with reduced modulus and stiffness (243). Thus, there is room 
for better treatment outcomes for surgical Achilles tendon repairs.   
Due to the high incidence of Achilles injuries, the rat Achilles tendon model has been 
frequently used to model tendinopathy, repair treatment modalities, and rehabilitation protocols 
(244). Due to the location and size of the tendon, the Achilles tendon is more easily accessible than 
other tendon models. Like all acute injuries, the model does not recapitulate the environment of 
chronic degeneration that is associated with many tendon injuries. Moreover, anatomy and 
kinematics of tendons in animals do not usually match those of humans. Despite these limitations, 
animal models provide useful information on cellular and tissue level principles in a living 
organism (244).  
Once efficacy is established in a small animal model, the tissue engineering scaffold must 
be tested in larger animal models with the scaffold located in the correct anatomical location for 
which the device is designed for. If results remain favorable, the device must then be proven to be 
safe. Only then can human trials be conducted. The easiest route to obtaining FDA approval is to 
follow the path of an existing FDA approved device (245).  
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3! Specific Aim III: To conduct bioactive feasibility assessments of an insulin delivery 
matrix system in combination with bone marrow derived MSCs, in-vivo.   
 
3.1! Materials and Methods  
3.1.1! Cell Attachment  
The effectiveness of cell loading on the scaffold was tested using both dynamic and static 
conditions. After sterilization, 1x1cm scaffolds undergoing static seeding, were placed in 48-well 
plates. A volume of 200ul of media containing approximately 500,000 cells were added to the top 
of the scaffolds. The scaffolds were incubated at 37degC and collected at 1,2,3,4,6,12, and 24 
hours after seeding. Scaffolds receiving dynamic seeding, were placed in sterile 2ml tubes with 
200ul of media containing approximately 500,000 cells and were gently rocked. Scaffolds were 
collected at 1,2,3,4,6,12, and 24 hours after seeding. At collection time point all scaffolds washed 
and processed for DNA content as previously described.  
 
3.1.2! Donor Cell Harvest  
Male Sprague dawley rats, approximately 8 weeks old, were euthanized using CO2 
asphyxiation. The long bones of all limbs were dissected and collected from the animal. All 
muscles and other tissues were cleared off from the bone. The bone was then dipped in 70% 
ethanol. In a biological sterile hood, the ends of the long bones were cut using bone scissors. An 
18-gauge needle was used to flush the bone canal with DMEM. The cell media was filtered through 
a 20µm filter and collected in a 50ml conical tube and underwent centrifugation. Centrifugation 
resulted in the separation of blood red cells and bone marrow stromal cells. The stromal cells were 
 98 
isolated and plated onto 10mm tissue culture plates and allowed to proliferate. Cells were passaged 
up to P2 and used as donor cells for cell seeded scaffolds.   
 
3.1.3! Scaffold Preparation  
Scaffolds were cut into 3x3mm squares and sterilized with 70% ethanol and UV light, as 
previously described. Scaffolds with insulin functionalization underwent EDC conjugation, as 
previously described, 48 hours prior to implantation. In brief, sterilized scaffolds underwent EDC 
conjugation with insulin using filtered aqueous solutions. A cell suspension of 1 million cell 
density were added to the scaffold and allowed to attach to the scaffold for 24 hours prior to 
surgery. All scaffolds were incubated in DMEM prior to implantation.  
 
3.1.4!  Surgical Procedure  
Female Sprague dawley rats, (9-12-week old) were used in the study. Animals were housed 
in the university animal tower for a minimum of 48 hours prior to operation to allow animals to 
acclimate to the new surroundings. All operations were conducted in the UConn Health small OR 
room. Prior to surgery, the animal was anesthetized with isoflurane, (level 2) using a chamber box. 
The animal was then transferred to a nose cone connected to a scavenger system. The left ankle 
was shaved and cleaned with alternating chlorhexidine and povidone-iodine, 3x. The animal was 
given a half dose of buprenorphine and transferred to the operating table. A 3cm incision was made 
over the left Achilles tendon. Once exposed, the Achilles tendon was isolated from the surrounding 
fascia. At 5mm away from the calcaneus, the tendon was fully ruptured with a scalpel. The tendon 
was then repaired according to treatment group 1) defect only (no repair) 2) suture repair 3) neat 
scaffold repair with PCL/CA blend scaffold 4) Insulin functionalized scaffold 5) Neat scaffold 
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with cells 6) Insulin functionalized scaffold with cells. A 6-0 prolene sutures using a Kessler stitch 
technique was first used to augment the tear for repair groups. The scaffold groups were augmented 
with a 3mmx3mm scaffold placed over the repair using 7-0 prolene sutures. The skin was sutured 
closed with 5-0 sutures and surgical glue. The animal was given pure oxygen and the remaining 
half dose of buprenorphine. The animal was given two doses a day, 8-14 hours apart, of 
buprenorphine for two days after the surgery. Animals were housed individually post-surgery for 
two weeks. After two weeks, animals were group housed.  
 
 
Figure 5.1. Schematic of surgical model. The tendon was cut 5mm away from the bone 
calcaneus. The tendon was either left with no repair, sutured only, or sutured with the 
scaffold overlaying the tendon repair.    
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3.1.5!  Blood Glucose Testing  
Due to the potential of insulin to affect blood glucose levels, blood from the rat tail vein 
were collected weekly for four weeks. The animals were first anesthetized with isoflurane. A 25-
gauge needle was used to prick the lateral tail vein. A droplet of blood was then collected on a 
glucose monitor strip and read using a glucose reader. Readings above 60mg/dL were considered 
normal.  
 
3.1.6! Sample Collection 
At 4 and 8 weeks, animals were euthanized using CO2 asphyxiation. The repaired tendon 
was exposed and isolated. Tendon samples for histological evaluations were cute at the calcaneus 
and muscle attachments, washed with PBS, and placed in formalin. Samples used for 
biomechanical testing, were removed with the muscle and foot attached. The tissue was wrapped 
in sterile gauze soaked in PBS and immediately stored in -80°C until analysis.  
 
3.1.7! Histological evaluation  
The samples were fixed at -20°C for 3 days, washed with copious PBS and stored in 70% 
ethanol. Samples were embedded in paraffin blocks, sectioned and stained with hematoxylin and 
eosin and Trichrome (Gomori). Separate slides were used for immunohistochemistry staining of 
collagen I and collagen III. All slides were scanned and digitized using an Aperio CS2 slide 
scanner, with 20x magnification. A total of 12 fields starting from 2cm away from the calcaneous 
to 8cm (2 fields at each 1cm increment) from 3 separate specimens were evaluated for all image 
quantifications.     
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Hematoxylin and eosin stain was used to count the number of cells in the tissue, using 
ImageJ plugin. Hemotoxylin stains cell nuclei a deep blue allowing demarcation of the nuclei. 
Images were converted to 8bit and threshold was adjusted to select only nuclei. To count cells, the 
particles were analyzed, using a 30 square pixel size minimum, as shown in Figure 5.2.  
The trichrome stain differentiates between muscle, collagen, and nuclei, where the 
components are dyed red, blue and black, respectively. Dyes were separated using ImageJ plugin, 
color deconvolution. The relative percent area of blue and red dye were recorded.      
Collagen staining was quantified using ImageJ analysis, as previously described (31).  A 
total of 12 fields per sample (n=3), at 20x magnification were assessed for total area of collagen I 
and collagen III. The same areas evaluated on a single sample were kept constant for collagen I 
and collagen III. The image was separated using ImageJ color deconvolution plugin for HDAB 
(see Figure 5.3). The amount of brown stain was evaluated by selecting areas at a maximum 
threshold. Threshold values were kept constant for all samples. The ratio was obtained by the total 
area of collagen I staining divided by the total area of collagen III staining.   
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Figure 5.2. Protocol schematic for determining cell number using ImageJ analysis. The H&E 
image is converted to an 8bit image. Cells are chosen by thresholding the nuclei and analyzed 
using particle analysis. All particles with at least 30 square pixel area are counted.      
 
 
 
 103 
 
Figure 5.3 Method to quantify collagen expression using ImageJ analysis, involves color 
deconvolution plugin and measuring the area at a common threshold value.  
 
3.1.8! Second Harmonic Generation  
A ZEISS 780 confocal laser scanning microscope was used to generate second harmonic 
generation (SHG) images of unstained 5µm thick tendon sections using 900nm Ti:Sapphire laser. 
Tiled images were obtained covering a 1.2x1.2mm area. For each sample, 6 images were obtained 
along the length of the tendon, covering 6mm area (Figure 5.4A). Image analysis was conducted 
as previously described (246, 247). Briefly, ImageJ was used to process images to FFT plots. A 
circular projection was drawn at the center of the FFT plot and ImageJ Oval Profile plugin was 
used to calculate pixel intensity along the radius of the circular projection. The summed pixel 
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intensities were plotted against the angle of acquisition producing a FFT alignment plot. FFT peak 
was used a measure of collagen alignment (Figure 5.4.B).   
 
 
 
Figure 5.4.  A) Protocol schematic for processing SHG images, using Fast Fourier 
Transformation analysis.  B) Fast Fourier Transformation of SHG images to create FFT 
alignment graphs.  
 
A 
B 
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3.1.9! Biomechanical Testing  
Biomechanical testing was conducted using an Instron tensile 5869 machine. The foot of 
the animal was encased in block of orthodontic resin. In one set of studies, the muscle attachment 
was gripped by a custom device that was directly attached to the load cell. The device was 
fabricated using designs modified from Wieloch et al. (248). The original design contained 
compartments for liquid nitrogen. The modified design contained compartments to hold dry ice 
instead of liquid nitrogen as shown in Figure 5.2. The dry ice freezes the muscle attachment to 
prevent slippage. In another set of testing, the muscle was glued between sand paper. No 
differences were found between the set of test used with the custom cryoclamp or the sandpaper 
method. The tensile tests were conducted with ramp speed of 0.1mm/s using a rectangular 
geometry. Values for tensile strength and modulus were obtained.  
 
3.2! Results 
3.2.1! Cellular Attachment 
 
Figure 5.5. Amount of cellular DNA present on scaffolds after seeding. Scaffolds 
dynamically seeded, after 24 hours showed highest amount of DNA concentration.  
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Dynamic seeding was shown to be superior in terms of DNA concentration when compared 
to static seeding thus indicating higher cellular attachment. The largest jump in the amount of DNA 
concentration was from 1 hour to 2 hours in static seeding and from 6 to 24 hours in dynamic 
seeding, as shown in Figure 5.5. Thus, to allow for the greatest amount of cell attachment, all 
scaffolds with donor cells were dynamically seeded for 24 hours prior to implantation.   
 
3.2.2! Surgical Procedure  
The study consisted of A total of 9 animals per group per time point. Surgical procedure is 
depicted in Figure 5.6. All animals survived surgery with no complications for the remainder of 
the study.  
 
 
Figure 5.6. (i) Surgical area prepped for surgery (ii) Exposed Achilles tendon (iii) Plantaris 
tendon is separated and excised (iv) Achilles tendon is separated from surrounding tissue (v) 
A suture across the distal end of the tendon is placed prior to cutting the tendon vi) A distance 
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of 5mm is measured distal to the calcaneous (vii) The tendon is cut (viii) Gap displayed 
between the two tendon ends (ix) Using a Kessler knot, the tendon ends are approximated 
(x) PCL/CA scaffold measuring 3x3mm (xi) The scaffold is sutured over the repaired area 
(xii) The scaffold over the repaired tendon (view 1) (xiii) The scaffold is over the repaired 
tendon (view 2) (xiv) The incision is closed (xv) Animal is mobile immediately after surgery. 
 
3.2.3! Blood Glucose Levels  
 
Figure 5.7 Glucose monitoring of rats showed no difference in glucose measurement 
between rats treated with and without insulin.  
Glucose blood was collected from the rat tail vein weekly for 4 weeks, post-surgery. The 
blood was placed on a glucometer strip and the blood glucose measurement was taken. There was 
no difference in the glucose blood levels of animals treated with scaffolds with or without insulin. 
This indicates the implanted insulin did not have an effect on the overall blood glucose levels of 
the animals. 
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3.2.4! Gross Morphology  
 
 
Figure 5.8. Gross morphology of tendons at 4 and 8 weeks. 
 
The morphology of repaired tendons at 4 and 8 weeks showed increased scar tissue when 
compared to native uninjured tissue (Figure 5.8). All groups had overall increased tendon size 
when compared to the native tissue. At 8 weeks, the scaffold is still visible for all scaffold groups.  
 
3.2.5! Cell Infiltration  
Overall, higher cells number were observed on the scaffold areas when compared to 
nonscaffolds areas for all scaffold treatment groups (Figure 5.9). At 4 weeks, there was 
significant increase in cell infiltration in the cell seeded groups when compared to defect and 
suture repair group. At 8 weeks, insulin scaffold group had the highest number of cells and was 
statistically significant from the defect group (Figure 5.10).  
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Figure 5.9. Representative images of H&E stains at 4 and 8 weeks from treatment groups. 
High cell infiltration into scaffold area can be seen in scaffold treatment groups.  
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Figure 5.10. Cell density tissues collected at 4 and 8 weeks. Note: native tendon has cell 
density of approximately 130 cells/.24mm2 
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Figure 5.11. Relative expression of SRY on cell seeded scaffold groups. Results indicate 
minimal presence of donor cells after 4 weeks, post-surgery.  
 
Donor cells contained male sex gene, sex determining region Y, (SRY). To see the amount 
of cells containing SRY, DNA collected from the tendon samples were collected and analyzed 
using qPCR. Within the DNA sample, at most, there was approximately 0.04% of SRY gene found 
from the tendons treated with insulin functionalized scaffolds. Though this was statically 
significant from the other scaffolds with donor cells, the very low percent indicates a very low 
chance of the presence of donor cells. 
 
 
3.2.6! Trichrome Stain  
At 4 weeks, all treatment groups displayed a statistically significant difference in the 
percent area of red (fuchsin) and blue (aniline) dye when compared to native Achilles tendon. 
Native tendon exhibited a strong red dye. At 8 weeks, an increase in red dye was observed with 
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scaffold treated groups. Defect and suture group maintained higher percent of blue dye, whereas, 
Ins scaffold and cell seeded groups had higher percent areas of red dye (Figure 5.11 & 5.12).  
 
Figure 5.12. Representative trichrome stain of treatment groups showing whole tendon 
specimens.  
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Figure 5.13. A) A total of 12 FOV were analyzed to determine the relative percent of blue 
and red dye in the tissues. B) Representative trichrome stain FOV with corresponding 
H&E stain. C) Quantification of relative red (fuscin) to blue (aniline) stain.  
 
3.2.7! Collagen Staining  
At 4 and 8 weeks, there was an overall stronger staining for collagen III than collagen I for 
all groups. At 4 weeks, defect and suture repair groups showed the lowest staining of collagen I, 
when compared to all scaffold groups. Tendons repaired with insulin scaffold with cells had the 
greatest amount of collagen I staining, which was statistically significantly from non-scaffold 
groups and all other groups at 4 and 8 weeks, respectively (Figure 5.13). At 8 weeks, collagen III 
levels remained overall constant for all groups from 4 to 8 weeks. However, cell seeded groups 
exhibited statically significant collagen III staining when compared to all other groups at both 4 
and 8 weeks (Figure 5.14). A higher ratio of collagen I to collagen III is observed on all scaffold 
groups with cells and insulin scaffold when compared to no repair, suture, or scaffold groups at 4 
weeks. At 8 weeks, no repair and suture groups remain low in collagen I to III ratio. The insulin 
scaffold with cells group had the highest ratio at 8 weeks (Figure 5.15). Native tendon was found 
to have a collagen I to collagen III ratio of approximately 2.0.   
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Figure 5.14. A) 12 FOV for the measurement of Collagen I. B) Representative images for 
each group at 4 and 8 weeks. C) Quantification of collagen I staining. Markings indicate 
statistical significance compared to Ins Scaffold+ cells, unless otherwise indicated. *p<0.05, 
**p<0.01, ***p<0.001 
A 
B 
C 
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Figure 5.15. A) 12 FOV for the measurement of Collagen III. B) Representative images for 
each group at 4 and 8 weeks. C) Quantification of collagen III staining. Markings indicate 
statistical significance compared to Ins Scaffold+ cells, unless otherwise indicated. *p<0.05, 
**p<0.01, ***p<0.001  
A 
B 
C 
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Figure 5.16. A) Representative images of collagen I and collagen III of the same area. B) 
Quantification of the ratio of collagen I to collagen III. 
 
 
 
A 
B 
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3.2.8! Second Harmonic Generation 
Second harmonic generation images were used to quantify the overall alignment of 
collagen fibers of the healing tendons at 4 and 8 weeks. Lower alignment was found with insulin 
scaffold and cell seeded scaffolds at early time point, 4 weeks. However, at 8 weeks significantly 
greater alignment was associated with cell seeded scaffold groups.   
 
 
 
 
Figure 5.17. Quantificaiton of SHG images indicating overall collagen alignment.  
 
 
 
 
3.2.9! Biomechanics  
At 8 weeks all groups displayed tendons that were thicker in width when compared to 
native uninjured tendon (data not shown). The thickening of repaired tendons is common 
phenomenon observed in injured tendons (249-251). At 8 weeks, treatment groups demonstrated 
a significant decrease in ultimate tensile stress and modulus when compared to native Achilles 
tendon. All treatment groups showed approximately 10% of the total tensile strength of uninjured 
tendon. However, no differences were found amongst the treatment groups in tensile strength, 
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indicating insulin scaffold and insulin scaffold with cells had no detrimental, or beneficial effect 
on the biomechanical properties of the tendon at 8 weeks. All tendon failed at the bone, where the 
tendon was removed from its bony attachment.  
 
 
 
Figure 5.18. Mechanical testing set up of tensile testing. Bone end was encased in orthodontic 
resin and the muscle end was held by parallel plates with sand paper. Breakage for all groups 
occurred at the bony end, where the tendon detached from the bone.  
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Figure 5.19. A) Stress vs. elongation graph of treatment groups after 8 weeks of healing. B) 
Quantification of tensile stress and modulus of treated tendons showed no significant 
difference between groups.  
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Figure 5.20. Gene expression of pro-inflammatory and anti-inflammatory markers from 
tissues collected at 4 and 8 weeks.  
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Figure 5.21. Gene expression of matrix markers from animal tissues collected at 4 and 8 
weeks.   
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3.2.10 Inflammation and Remodeling mRNA Expression  
 At 4 weeks, there was an upregulation of inflammatory markers IL-1ß for all groups, with 
a decrease at 8 weeks. All other inflammatory markers were relatively more highly expressed at 8 
weeks when compared to 4 weeks. There was a significant increase of Ly6c in the suture repair 
group at 8 weeks when compared to all others. The marker CCL2 was significantly higher in the 
scaffold group at 8 weeks compared to others and CD68 was significantly expressed by insulin 
scaffold+cell group when compared to defect, insulin scaffold, and scaffold+cell groups. The 
suture group expressed the highest expression of anti-inflammatory markers IL10 and CD168 at 8 
weeks when compared to all other groups.   
 No statistical differences were found in the mRNA expression of tendon matrix markers 
between groups. However, expression of all matrix markers were elevated at 8 weeks when 
compared to 4 weeks.    
 
4! Discussion 
The goal of these studies was to evaluate the feasibility of insulin as a bioactive factor in 
promoting tendon healing. Our prior in vitro studies indicated that mesenchymal stem cells treated 
with insulin had increased expression of tendon markers as well as collagen synthesis (66). The 
results from the previous experiments have shown a positive effect of insulin in supporting the 
expression of tendon markers in mesenchymal stem cells (Chapter 3). Furthermore, the bioactivity 
of insulin was shown to be preserved in an insulin functionalized scaffold (Chapter 4). To 
determine the performance of the insulin functionalized scaffold in an in-vivo environment, the 
scaffolds were implanted into a rat tendon defect model, along with bone marrow derived 
mesenchymal stem cells. Prior to implantation, studies showed that dynamic seeding technique 
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resulted in higher scaffold cellular attachment when compared to static seeding. Moreover, an 
incubation period of 24 hours allowed for the greatest number of cell attachment (Figure 5.5). Due 
to these findings, all cell seeded scaffolds were dynamic seeded for 24 hours prior to implantation. 
During the study, animals who received treatment with insulin scaffolds did not show decreased 
glucose levels during a 4-week study period (Figure 5.6). This indicates the implanted insulin did 
not have a systemic effect on the animals.  
At 4 and 8 weeks all groups displayed tendons that were thicker in width when compared 
to native uninjured tendon, as shown in Figure 5.7. The thickening of repaired tendons is common 
phenomenon observed in injured tendons (39-41). From the gross morphology, insulin scaffolds 
showed better tissue integration when compared to the plain scaffolds. Since the insulin scaffolds 
and plain scaffolds were made from the same material composition and handled the same way, it 
leads one to believe that the immobilized insulin may be creating a more biocompatible 
environment.  A major factor in determining the biocompatible of an implant is the binding of 
nonspecific proteins to the surface of the scaffold (42). The rapid adsorption of proteins to an 
implant occurs immediately after implantation and can trigger an immune response (43). The 
presence of the immobilized insulin on the surface of the scaffold may have contributed to a lower 
binding of nonspecific proteins. There does not appear to be any differences in gross morphology 
between cell-seeded scaffolds and non-seeded scaffolds.  
Within the scaffolds, cells were found to infiltrate throughout the entirety of the scaffold 
with vascularization present. This indicates the porosity of the scaffold was adequate for cell and 
vascular infiltration. A large body of evidence exists indicating the presence of donor cells or 
exogenous cells, promotes better healing and regeneration (30, 39, 45-47). However, the exact role 
of these donor cells remains elusive. Some studies have shown the continued presence of donor 
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cells weeks after implantation. Lee et al. observed fluorescently labeled human donor cells in a rat 
Achilles tendon defect after 4 weeks, along with human specific collagen type I and tenascin C 
(48). This indicates the implanted human mesenchymal stem cells contributed to the building of 
the extracellular matrix, which resulted in better healing. Others have suggested a paracrine role 
for donor cells (49-51). Caplain et al. describes the indirect effects of mesenchymal stem cells as 
trophic activity through release of growth factors and cytokines. Greater resolution of tendon repair 
was observed on rotator cuff supraspinatus tendons treated with exogenous mesenchymal stem 
cells, despite low presence of the donor cells, at six weeks (30). In the present study, at 4 weeks, 
less than 0.05% of DNA was evidenced to contain the male sex gene SRY (Figure 5.13). This 
indicates that by 4 weeks, the presence of donor cells was very low. However, repair groups that 
contained donor cells, showed higher increase of cellular infiltration within the scaffold at 4 weeks 
(Figure 5.14). Cell infiltration into the scaffold may indicate a higher efficacy of donor cells in 
encouraging cellular attachment and migration (40). The donor cells may have released factors 
that caused host cells to migrate to the area, resulting in greater cellular infiltration to the scaffold 
(52). Our studies did not include an evaluation of cells types, so it remains a question as to what 
types of cells infiltrated the scaffold. Future studies will need to be done to elucidate the cell 
populations present on the scaffold.  
The expression of collagen is ubiquitous in tendon, as it makes up the majority of tendon 
tissue. Traditionally, trichrome stains collagen blue/green, whereas muscle fibers and erythrocytes 
stain red. However, it was observed that native tendons, with no injury stained brightly red. Similar 
findings were found in Martinello et al. where Masson Trichrome staining is suggested to be a 
useful measure of collagen spatial arrangement of tendon lesions (252). Healthy tendon was found 
to have a high percentage of fuchsin, red dye and low percent of aniline, blue dye. After injection 
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of collagenase, blue dye was observed, peaking at 30 days-post injection, with gradual decrease 
for the remainder of the study (120 days). This observed phenomenon of collagen fibers staining 
red in healthy tissue may be related to the affinity of the dyes to bind to the collagen fibers. Fuchsin 
dye binds to all tissues, whereas aniline dye preferentially dyes collagen fibers more readily. Thus 
collagen blue/green staining is the result of the displacement of fuchsin dye by aniline dye (253). 
Craik and McNeil were the first to report a change in dye affinity between stretched and relaxed 
collagen during trichrome staining, observing that stretched collagen had greater affinity to the red 
dye (254). Flint et al. attempted to elucidate the reason for this phenomenon (253). They postulate 
that in a relaxed tendon state, there is lower availability of positively charged binding sites for the 
anionic dyes to bind to, due to internal electrostatic pairing with adjacent negatively charged 
groups. However, in stretched or tensioned tendons, the ionic groups are sufficiently widely 
separated, such that extensive interactions within the tissue do not occur. Thus, there are more 
available active dye bindings sites that retain the red dye and would require significantly more 
time for color displacement to occur (253). If such is the case, trichrome staining may perhaps give 
an indication of the tensioned state of the tendon and subsequently it’s functional use. This is in 
alignment with the findings of Martinello et al. who found blue dye evident in degenerated tendons, 
as these tendons would presumably be experiencing lower loads than healthy tendons, which 
stained red. As the tendon heals, the animal may gradually be putting more force onto the tendon, 
thus resulting in a greater affinity for the red dye. Likewise, in this study, it may be the case that 
at 4 weeks, less tension was applied to the tendon at the earlier stages of healing resulting in 
majority blue staining for all groups. At 8 weeks, with greater healing, animals may have been 
able to apply more weight onto the leg, thus increasing tension in the tendon. Thus, greater fuchsin 
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staining in the scaffold treated groups may be an indication of increased tension and utilization of 
the tendon, compared to defect and suture repair groups.  
Immunostaining of collagen I and collagen III provide more details of the ECM of the 
healing tendon. The deposition of collagen III is one of the initial steps in tendon healing and 
represents an unorganized collagen matrix. Collagen III is subsequently replaced by collagen I as 
the tendon heals and remodels resulting in a more organized and aligned matrix. Thus, the ratio of 
collagen I: collagen III is used as a measure of collagen organization (31). In our studies, native 
tendon had a ratio of 2. For all groups, at both time points, greater staining of collagen III was 
observed. Thus, collagen ratios remained below 1. At 8 weeks, higher ratios of collagen I to 
collagen III were found with all scaffold groups when compared to defect and suture repair. 
Moreover, insulin scaffold with cells had the highest ratio at 8 weeks. However, this trend was not 
significant owing to large standard deviations, which may be a consequence of error propagation 
that can result from calculated values. Nevertheless, the cell seeded insulin scaffold group 
demonstrated the highest ratio of collagen I, suggesting that the combination of insulin 
functionalized scaffold and cells may contribute to a higher organization of the ECM during the 
remodeling phase. Analysis of SHG images of the tendons corroborate these findings as greater 
collagen alignment was statistically higher with the insulin scaffolds with cells. However, neat 
scaffold with cells also demonstrated higher alignment, suggesting organization may be a result of 
donor MSCs, rather than insulin.  
Cartilage cells were present in all groups. Cartilage cells were identified through rounded 
cell shape with large cytoplasmic area arranged in characteristic whorls (251). At four weeks, 
whorls were observed in samples and by 8 weeks, large cartilage nodule formations, along with 
bone were present in some areas of the tendons. The occurrence of cartilage formation was 
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independent of treatment and appeared at random. Endochondral ossification is a well-documented 
phenomenon that occurs with tendon tenotomy (251). Rooney et al. suggests tendon cells undergo 
metaplasia following injury and produce regions of fibrocartilage. Future studies will need to 
address this issue. Future studies will need to address this issue.  
 Disorganization the ECM has been linked to scar tissue with inferior mechanical properties. 
Conversely, higher organization of the ECM generally indicate better tissue healing and improved 
mechanical properties. However, though histological data suggested greater organization of the 
tendon ECM associated with the insulin+cell group, this was not translated to an increase in 
biomechanical strength. All treatment groups showed significantly lower mechanical properties 
than native tendon in both tensile stress and elastic modulus at 8 weeks. Several studies have 
reported positive histology data with no biomechanical gains at late time points (179, 255, 256). 
Significant gains in biomechanical properties are often found at early time points up to two weeks 
(256). Early gains in mechanical strength, but not at later time points may be due to several reasons 
including waning effects of treatment. Since the scaffold was functionalized with insulin, it may 
be possible that an increase in cells and ECM matrix made it more difficult for cells to gain access 
to the insulin protein, thus not being beneficial at later time points. Furthermore, 8 weeks may have 
been a long enough period where any differences between groups disappeared due to the normal 
course of healing. Mechanical testing at an earlier time point may produce differences among the 
groups. Additionally, it may be the case that histological gains from insulin+cells group were not 
substantial enough to make a difference in the biomechanical properties of the tendon. Though 
scaffolds were found to be adequate in promoting collagen in-vitro environment, the in-vivo 
environment presents a completely different dynamic and may warrant separate dosing 
optimization experiments in an in-vivo setting.   
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Pro-inflammatory and anti-inflammatory markers were evaluated to render 
immunomodulatory information regarding insulin and BMSCs (Figure 5.19). In evaluating the 
mRNA expression of tendon samples, due to large standard deviations, there were few significant 
differences within the treatment groups. However, trends indicate temporal expression of markers. 
There was a higher expression of IL-1ß, a classical pro-inflammatory marker at 4 weeks when 
compared to 8 weeks. All other markers tended to be upregulated at 8 weeks. This includes the 
pro-inflammatory markers, Ly6c, CCL2, CD68, CCR7, and IL-6 and anti-inflammatory markers, 
IL-10 and CD168. The upregulation of both pro- and anti-inflammatory markers may indicate that 
there is a heterogeneous population of cells and macrophages in the healed tissues. Evaluation of 
ECM markers also showed upregulation at 8 weeks for all groups (Figure 5.20). The large standard 
deviations prevented any statistical differences between the groups. A higher sample number in 
future studies will help clarify and elucidate any immunomodulatory effects of insulin and 
BMSCs.    
To the best of our knowledge, this is the first studies to evaluate the feasibility of insulin 
for tendon healing and regeneration in an in-vivo model. In general, it was observed that tendons 
healed with insulin in combination with mesenchymal stem cells showed increased expression of 
collagen I and overall greater organization of the ECM through collagen alignment. Though the 
present study provided some evidence for the potential use of insulin functionalized scaffolds in a 
tendon injury, future studies should focus on optimizing the in-vivo insulin dosage, as well as the 
immunomodulatory effects of insulin and BMSCs.  
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Chapter 6: Summary and Future Directions 
Surgical treatments for tendon injuries are prone to retears and have shown to be limited in 
functional recovery (28). New advances in the field of tissue engineering opens new possibilities 
in the management and treatment of tendon injuries through the use of biomimetic scaffolds, stem 
cells, and biomolecules. To date, no standardized media has been confirmed for the differentiation 
of stem cells to tendon lineage, however studies have shown the use of various growth factors to 
induce tendon cell phenotype, as well as collagen synthesis. Insulin-like growth factor-1 (IGF-1) 
has consistently been shown to induce collagen synthesis and to improve tendon healing (51, 52). 
However, the clinical use of growth factors is limited due to the difficulty in obtaining FDA 
approval, short half-life, and potential risks such as cancer (257). Thus, the overall investigative 
focus of this thesis was to determine the efficacy of insulin, a homologous molecule to IGF-1, in 
tendon differentiation and tendon healing.   
In Aim I, mesenchymal stem cells were treated with insulin supplemented media, as a one-
time dose or continuous dose. Data showed mitotic effects of insulin to be minimal at 
concentrations below 1ug/mL. Preliminary data showed increased metabolic activity of cells 
treated with 1ug/mL or higher of insulin after 24 hours. In terms of differentiation, continuous 
treatment of insulin at a minimum of dose of 100ng/ml concentration increased and maintained 
expression of tendon cell and ECM markers. The data supports that insulin treatment can be used 
to enhance the differentiation of mesenchymal stem cells towards tendon phenotypic development.   
In Aim 2, PCL/cellulose acetate blend scaffolds were fabricated and characterized for their 
ability to act as a cell and insulin delivery vehicle. A composition of 75:25 ratio of PCL to cellulose 
acetate was found to be optimal amongst the groups tested for maximum cell and protein delivery, 
as well as mechanical property. Insulin was chemically linked to the scaffold surface via amide 
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bonding. In this way, insulin is tethered to the scaffold and is not readily released to avoid burst 
release of insulin into the body. Biological studies showed mesenchymal stem cells seeded on 
insulin functionalized scaffolds expressed tendon markers similarly to findings found in Aim 1, 
using insulin supplemented media. Thus, the insulin protein on the functionalized scaffold 
remained bioactive.    
Lastly, in Aim 3, the performance of the insulin functionalized scaffold was evaluated in-
vivo, in a rat Achilles tendon model. The results of the animal studies showed significantly more 
collagen staining and greater ECM organization with tendons treated with the insulin scaffold in 
combination with mesenchymal stem cells. Disorganization the ECM has been linked scar tissue 
with inferior mechanical properties. Conversely, higher organization of the ECM generally 
indicate better tissue healing and improved mechanical properties. However, no significant 
differences were found in terms of tensile strength or modulus among the treatment groups at 8 
weeks. Several studies have reported positive histological data, with minimal mechanical gains at 
later time points (ref). A limitation of the study includes the lack biomechanical testing at earlier 
time points. Differences in biomechanical properties have been reported at 2- and 4-week post 
injury. Future studies should look at performing biomechanical testing at earlier time points.  
The combination of insulin at the wound site and donor mesenchymal stem cells did appear 
to improve tendon healing through greater organization of the ECM. The presence of donor cells 
is hypothesized to have a paracrine effect in recruiting native cells to the wound site, whereas 
insulin is hypothesized to increase collagen synthesis, similar to the effects of IGF-1. The role of 
exogenous or donor cells are not yet fully understood. Several studies suggest donor cells take an 
active role through direct ECM protein synthesis, while others support a more indirect role through 
paracrine signaling. The role of macrophages in tendon healing have also been investigated and 
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found to be involved during the inflammatory and remodeling stages. Monocytes, along with 
neutrophils quickly infiltrate the tendon injury within the first 24 hours and after several days, the 
monocytes differentiate into macrophages. Two phenotypes of macrophages have been observed. 
Macrophages in the early stages are needed to digest necrotic materials. These macrophages are 
designated as M1 and are considered pro-inflammatory as they promote the expression of 
inflammatory factors such as IL-1, TNF- ", IL-6, and nitric oxide. The other macrophage 
phenotype, known as M2 is considered to be anti-inflammatory and helps to coordinate ECM 
deposition and tissue repair. Recently published work by Zheng et al. studied the effect of bone 
marrow mesenchymal stem cells on the polarization of macrophages (258) and reported that co-
culture with MSCs reduced macrophage differentiation into M1 phenotype and reduced 
inflammation. Sugg and colleagues noted that the expression of M1 markers peaked at 2 weeks 
post Achilles tendon transection, whereas expression of M2 markers appeared at 4 weeks (259). 
Thus, future studies looking to gain mechanistic insight into the role of insulin, donor MSCs, and 
their combination on tendon healing, should look at early gene and protein expressions at 1-4 week 
post-surgery.  
Collectively, the data supports the potential use of insulin in tendon repair and regeneration. 
More studies should be done to elucidate the mechanism in which insulin imparts its beneficial 
effects. There are three possible scenarios in which the insulin can be activating cellular 
mechanisms. In one scenario, insulin is binding to the IGF-1 receptor and propagating the IGF-1 
pathway. As previously mentioned, in the excess of insulin, insulin has a slight affinity to the IGF-
1 receptor. It has been proposed that therapeutic effects of IGF-1 on tendon healing is due to its 
activation of the P13k/Akt pathway, which promotes MSCs growth, mobilization and survival. 
Additionally, the possibility that insulin is binding to its own receptor cannot be ruled out. There 
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is evidence for anabolic actions of the insulin receptor for other musculoskeletal tissues such as 
bone and cartilage (153, 260). Thus, it is likely that the insulin receptor may also promote tendon 
ECM growth. Lastly, and perhaps the most complicated, would be the scenario in which the insulin 
molecule is binding to a hybrid receptor of insulin and IGF-1. Hybrid receptors of insulin and IGF-
1 are known to occur, but to what degree is still unknown. Interestingly, when IGF-1 receptors 
were removed from osteoblastic cells, enhanced signaling through the insulin receptor was 
observed. Authors predict that the increase in insulin receptor activity is due the lack of hybrid 
receptors that work to dilute the presence of insulin receptor homodimers (133). Mechanistic 
studies can be conducted through inhibition of receptors and seeing if the effects of insulin are 
preserved. Similar studies have been conducted in attempts to elucidate the separate effects of 
insulin and IGF-1. Additionally, since many mechanistic studies on the insulin family have been 
conducted mainly on terminally differentiated cells such as hepatocytes (69), cartilage (153), and 
osteoblast cells (144), mechanistic studies on mesenchymal stem cells would provide novel 
information. Few studies have been conducted with insulin treatment on MSCs for tendon 
applications. For example, the relative abundance of insulin receptors and IGF-1 receptors on 
mesenchymal stem cells have not yet been investigated, but may provide better understanding of 
the interaction of insulin on mesenchymal stem cells.  
Current work in the lab is investigating the potential of exendin-4, a novel antidiabetic 
agent which shares 53% homology with human glucagon-like peptide-1 (GLP-1). Exendin-4 was 
originally developed to improve glucose control, however recent studies have shown that it may 
also have a proliferative effect on cells (261-263). Ongoing studies in the lab are looking at the 
effects of exendin-4 as bioactive factor to aid in tendon regeneration. Current studies show positive 
results from exendin-4 treated cells with increased expression of tendon markers at the gene and 
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protein levels. Further studies can also look at insulin analogues as bioactive molecules. Structural 
modification of the insulin molecule has the potential to change its binding affinity to the IGF-1 
receptor. Modifications to the B-chain of insulin molecules increases its structural homology to 
IGF-1 and thus its affinity to the IGF-1 receptor (264, 265). Various insulin analogues has shown 
to have increased mitotic effects (266, 267). Interestingly, Hansen et al. reports the increased 
mitogenic potency of insulin analogues may not be due to a greater affinity to the IGF-1 receptor, 
but rather due to slower dissociation from the insulin receptor. The sustained activation of the 
insulin receptor tyrosine kinase results in the sustained phosphorylation of intracellular Shc 
protein, which is believed to be the cause of increased mitogenic activity (266).  
Another interesting avenue to explore is the efficacy of insulin on healing tendon injuries 
in diabetic conditions. Tendon injury studies on diabetic rats show compromised tissue healing 
when compared to healthy animals. Lower healing may be attributed to altered expression of 
collagen and MMPs (268), as well as lower fibroblast proliferation and decreased lymphocyte 
infiltration (269). It would be interesting to investigate if the application of insulin functioned 
scaffold on a tendon injury of a diabetic rat, improves tendon healing and biomechanics. Our 
findings have shown the feasibility of insulin to positively affect tendon healing and regeneration. 
Future in-vivo studies should also evaluate the effectiveness of different insulin loadings. The 
current work did not evaluate the optimal in-vivo dosing. It may be possible to achieve increased 
benefits of insulin at higher loading concentrations. However, care should be taken to limit the 
amount of insulin delivered to the animal within the range that does not affect the metabolic system 
of the animal.  
Another direction to explore is the possibility for insulin to be used for tissue engineering 
of interfacial tissues. Previous work has supported the use of insulin for bone, cartilage, and muscle 
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growth (reviewed in Chapter 3). The current work showed evidence for insulin for tendon 
regeneration. The wide availability and relatively cheaper costs of insulin compared to traditional 
growth factors makes insulin an attractive bioactive molecule. Relative concentrations seem to 
modulate its effect on cells. Higher concentrations have been used for bone applications, while 
concentrations for tendon tend to be lower. Insulin concentrations for cartilage differentiation are 
intermediate of those used in bone and tendon. Thus functionalizing a scaffold with an insulin 
gradient may promote better healing of interfacial tissues such as at the bony attachments of 
tendons and ligaments or at the interface cartilage and bone tissues.  
 Further work on improving the scaffold design for mechanical strength should also be 
considered for clinical translation. The current study focused on the feasibility and delivery of 
insulin in tendon healing, thus the scaffold was placed over the repaired tendon injury to act as a 
patch, rather than as a bridge, augmenting two tendon ends. Thus, the current study did not take 
into consideration the required mechanical strength needed to augment a tendon segmental defect. 
To improve the mechanical strength of the scaffold, multiple layers of electropsun sheets can be 
fabricated together into one unit. The layers may be altering sheets of micro- and nanofibers so as 
to impart mechanical strength on the scaffold from the microfibers and increased surface area and 
bioactivity from the nanofibers.  
 Since its discovery in the 1920s, insulin has been extensively researched in terms of its 
protein structure and metabolic actions. The advent of biotechnology to synthesize recombinant 
insulin has made a dramatic impact in the lives of diabetic patients, as well as its availability. 
Despite the wealth of knowledge of this protein, new discoveries of its anabolic effects on tissues 
have just come to light in recent past. This seemingly humble protein may have undiscovered 
potential in tissue engineering.  
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